THE FOUNDATION FOR AIDS RESEARCH: Form 990, tax year 2018

View the entire original 990 at ProPublica ↗

Organization: THE FOUNDATION FOR AIDS RESEARCH (EIN 13-3163817)
Tax period: 2018-10-01 to 2019-09-30
Filed: 2020-07-07
IRS object ID: 202001899349300025
Schema version: 2018v3.3
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule C
Schedule D
Schedule F
Schedule G
Schedule I
Schedule J
Schedule M
Schedule O

Return header ReturnHeader

Field	Value	IRS element (for citing)
Return	2020-07-07T09:19:57-05:00	ReturnTs
Tax Period End	2019-09-30	TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

Preparer Firm Name PreparerFirmName

Field	Value	IRS element (for citing)
Business Name Line1	GRANT THORNTON LLP	BusinessNameLine1Txt

Preparer US Address PreparerUSAddress

Field	Value	IRS element (for citing)
Address Line1	757 THIRD AVENUE 3RD FLOOR	AddressLine1Txt
City	NEW YORK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	100172013	ZIPCd

Field	Value	IRS element (for citing)
Return Type	990	ReturnTypeCd
Tax Period Begin	2018-10-01	TaxPeriodBeginDt

Filer Filer

Field	Value	IRS element (for citing)
EIN	133163817	EIN

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	THE FOUNDATION FOR AIDS RESEARCH	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
In Care Of	% BRADLEY JENSEN	InCareOfNm
Business Name Control	FOUN	BusinessNameControlTxt
Phone	2128061600	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	120 WALL STREET 13TH FLOOR	AddressLine1Txt
City	NEW YORK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	100053908	ZIPCd

Business Officer BusinessOfficerGrp

Field	Value	IRS element (for citing)
Person	BRADLEY JENSEN	PersonNm
Person Title	ASSISTANT TREAS./CFO	PersonTitleTxt
Phone	2128061703	PhoneNum
Signature	2020-07-06	SignatureDt
Discuss With Paid Preparer	Yes (true)	DiscussWithPaidPreparerInd

Preparer Person PreparerPersonGrp

Field	Value	IRS element (for citing)
Preparer Person	Scott Thompsett	PreparerPersonNm
PTIN	P00741490	PTIN
Phone	2125990100	PhoneNum

Filing Security Information FilingSecurityInformation

IP Address IPAddress

Field	Value	IRS element (for citing)
I Pv4 Address	69.248.129.53	IPv4AddressTxt

Field	Value	IRS element (for citing)
Federal Original Submission Id	26377520201895000003	FederalOriginalSubmissionId
Federal Original Submission Id	2020-07-07	FederalOriginalSubmissionIdDt
Filing License Type	P	FilingLicenseTypeCd
At Submission Creation Device Id	53F3E6840D653250BC02858DC60F5F1014CD29E2	AtSubmissionCreationDeviceId
At Submission Filing Device Id	8DDBE17DE0599195D17B7973BC5944EE8AD8D13D	AtSubmissionFilingDeviceId

Field	Value	IRS element (for citing)
Tax	2018	TaxYr
Build TS	2020-11-06 18:47:13Z	BuildTS

Form 990 IRS990

Doing Business As Name DoingBusinessAsName

Field	Value	IRS element (for citing)
Business Name Line1	AIDS RESEARCH FOUNDATION OR AMFAR	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Principal Officer	KEVIN FROST	PrincipalOfficerNm

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	120 WALL STREET 13TH FLOOR	AddressLine1Txt
City	NEW YORK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	10005	ZIPCd

Field	Value	IRS element (for citing)
Gross Receipts	$67,171,723	GrossReceiptsAmt
Group Return For Affiliates	false	GroupReturnForAffiliatesInd
Organization501c3	Yes (X)	Organization501c3Ind
Website Address	WWW.AMFAR.ORG	WebsiteAddressTxt
Type Of Organization Corp	Yes (X)	TypeOfOrganizationCorpInd
Formation	1983	FormationYr
Legal Domicile State	NY	LegalDomicileStateCd
Activity Or Mission	AMFAR IS DEDICATED TO ENDING THE GLOBAL AIDS EPIDEMIC THROUGH INNOVATIVE RESEARCH.	ActivityOrMissionDesc
Voting Members Governing Body	12	VotingMembersGoverningBodyCnt
Voting Members Independent	12	VotingMembersIndependentCnt
Total Employee	94	TotalEmployeeCnt
Total Volunteers	0	TotalVolunteersCnt
Total Gross UBI	$0	TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm	$0	NetUnrelatedBusTxblIncmAmt
PY Contributions Grants	$42,784,390	PYContributionsGrantsAmt
CY Contributions Grants	$40,275,703	CYContributionsGrantsAmt
PY Program Service Revenue	$0	PYProgramServiceRevenueAmt
CY Program Service Revenue	$0	CYProgramServiceRevenueAmt
PY Investment Income	$1,668,073	PYInvestmentIncomeAmt
CY Investment Income	$2,262,943	CYInvestmentIncomeAmt
PY Other Revenue	-$12,144,387	PYOtherRevenueAmt
CY Other Revenue	-$11,197,256	CYOtherRevenueAmt
PY Total Revenue	$32,308,076	PYTotalRevenueAmt
CY Total Revenue	$31,341,390	CYTotalRevenueAmt
PY Grants And Similar Paid	$12,574,033	PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid	$10,109,752	CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members	$0	PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members	$0	CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid	$11,259,330	PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid	$11,146,319	CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns	$735,053	PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns	$747,847	CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense	$5,823,450	CYTotalFundraisingExpenseAmt
PY Other Expenses	$14,468,481	PYOtherExpensesAmt
CY Other Expenses	$12,968,286	CYOtherExpensesAmt
PY Total Expenses	$39,036,897	PYTotalExpensesAmt
CY Total Expenses	$34,972,204	CYTotalExpensesAmt
PY Revenues Less Expenses	-$6,728,821	PYRevenuesLessExpensesAmt
CY Revenues Less Expenses	-$3,630,814	CYRevenuesLessExpensesAmt
Total Assets BOY	$69,536,136	TotalAssetsBOYAmt
Total Assets EOY	$64,157,103	TotalAssetsEOYAmt
Total Liabilities BOY	$16,985,457	TotalLiabilitiesBOYAmt
Total Liabilities EOY	$14,672,542	TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY	$52,550,679	NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY	$49,484,561	NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part III	Yes (X)	InfoInScheduleOPartIIIInd
Mission	THE FOUNDATION FOR AIDS RESEARCH IS AN INTERNATIONAL NOT-FOR-PROFIT ORGANIZATION INCORPORATED IN NEW YORK IN 1989. AMFAR WAS FORMED THROUGH THE UNIFICATION IN 1985 OF TWO NOT-FOR-PROFIT ORGANIZATIONS, THE AIDS MEDICAL FOUNDATION ("AMF"), INCORPORATED IN NEW YORK IN APRIL 1983, AND THE NATIONAL AIDS RESEARCH FOUNDATION, INCORPORATED IN CALIFORNIA IN AUGUST 1985. FIRST BASED IN CALIFORNIA, AMFAR TRANSFERRED ITS LEGAL DOMICILE TO NEW YORK IN 1989, USING THE INITIAL INCORPORATION DOCUMENTS OF AMF, MAKING IT AMFS LEGAL SUCCESSOR. AMFAR HAS OFFICES IN NEW YORK, NY, WASHINGTON, D.C., AND BANGKOK, THAILAND. ON MARCH 7, 2005, THE BOARD OF TRUSTEES OF THE AMERICAN FOUNDATION FOR AIDS RESEARCH APPROVED A CHANGE IN LEGAL NAME TO "THE FOUNDATION FOR AIDS RESEARCH." ON OCTOBER 18, 2005, THE NEW YORK STATE DEPARTMENT OF STATE APPROVED THIS CHANGE. IN ADDITION, THE FOUNDATION HAS SECURED APPROVAL FOR DOING BUSINESS AS (DBA) THE FOLLOWING: - AMERICAN FOUNDATION FOR AIDS RESEARCH - AMFAR - AIDS RESEARCH	MissionDesc
Significant New Program Srvc	false	SignificantNewProgramSrvcInd
Significant Change	false	SignificantChangeInd
Expense	$15,340,994	ExpenseAmt
Grant	$8,045,603	GrantAmt
Revenue	$0	RevenueAmt
Desc	RESEARCH: AMFAR SUPPORTS RESEARCH PROJECTS THAT EXPLORE NOVEL APPROACHES TO SCIENTIFICALLY SOUND BUT UNTESTED HYPOTHESES IN ALL AREAS OF RESEARCH ON HIV/AIDS, FUNDING GOAL-ORIENTED STUDIES THAT OFTEN LACK THE PRELIMINARY DATA REQUIRED FOR SUPPORT FROM TRADITIONAL GRANT MAKERS. THE FOUNDATION PLAYS A VITAL ROLE IN HIV/AIDS RESEARCH, IDENTIFYING CRITICAL GAPS IN KNOWLEDGE AND PROVIDING ESSENTIAL SEED MONEY THAT ENABLES GRANTEES AND FELLOWS TO TEST THE MERITS OF NEW CONCEPTS OR TECHNOLOGIES THAT SUBSEQUENTLY CAN BE VALIDATED THROUGH LARGE-SCALE STUDIES, SUCH AS THOSE FUNDED BY THE U.S. NATIONAL INSTITUTES OF HEALTH. FOR FURTHER DETAILS, SEE SCHEDULE O.	Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

Field	Value	IRS element (for citing)
Expense	$4,670,239	ExpenseAmt
Grant	$1,891,311	GrantAmt
Revenue	$0	RevenueAmt
Desc	TREAT ASIA: AMFARS TREAT ASIA (THERAPEUTICS RESEARCH, EDUCATION, AND AIDS TRAINING IN ASIA) PROGRAM IS A NETWORK OF HOSPITALS, CLINICS, AND RESEARCH INSTITUTIONS WORKING WITH CIVIL SOCIETY TO ENSURE THE SAFE AND EFFECTIVE DELIVERY OF TREATMENTS FOR HIV AND ITS CO-INFECTIONS TO ADULTS AND CHILDREN ACROSS THE ASIA-PACIFIC THROUGH RESEARCH, EDUCATION, AND ADVOCACY OF EVIDENCE-BASED HIV-RELATED POLICIES. THE TREAT ASIA NETWORK ENCOMPASSES 21 ADULT AND 20 PEDIATRIC SITES THROUGHOUT THE REGION, WHICH COLLABORATE ON A VARIETY OF PROJECTS. FOR FURTHER DETAILS, SEE SCHEDULE O.	Desc

Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp

Field	Value	IRS element (for citing)
Expense	$4,097,084	ExpenseAmt
Grant	$0	GrantAmt
Revenue	$0	RevenueAmt
Desc	PUBLIC INFORMATION: AMFAR SEEKS TO TRANSLATE AND DISSEMINATE INFORMATION ON IMPORTANT HIV-RELATED RESEARCH, TREATMENT, PREVENTION, AND POLICY ISSUES FOR DIVERSE AUDIENCES AND TO INCREASE AWARENESS AND KNOWLEDGE OF THE PANDEMIC. AMFAR PUBLISHES A WIDE RANGE OF EDUCATIONAL MATERIALS, MAINTAINS AN INFORMATIVE WEBSITE, AND ENGAGES RESPECTED PUBLIC FIGURES, HIV/AIDS SCIENTISTS, AND POLICYMAKERS IN COMMUNICATING THE NEED FOR CONTINUED RESEARCH TO DEVELOP NEW METHODS OF PREVENTION, TREATMENT, AND, ULTIMATELY, A CURE FOR HIV. FOR FURTHER DETAILS, SEE SCHEDULE O.	Desc

Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp (2 entries)

ExpenseExpenseAmt	GrantGrantAmt	RevenueRevenueAmt	DescDesc
$2,049,139	$77,995	$0	public policy
$268,341	$94,843	$0	GMT Initiative

Field	Value	IRS element (for citing)
Total Other Prog Srvc Expense	$2,317,480	TotalOtherProgSrvcExpenseAmt
Total Other Prog Srvc Grant	$172,838	TotalOtherProgSrvcGrantAmt
Total Other Prog Srvc Revenue	$0	TotalOtherProgSrvcRevenueAmt
Total Program Service Expenses	$26,425,797	TotalProgramServiceExpensesAmt
Described In Section501c3	Yes (true)	DescribedInSection501c3Ind
Schedule B Required	Yes (true)	ScheduleBRequiredInd
Political Campaign Acty	false	PoliticalCampaignActyInd
Lobbying Activities	Yes (true)	LobbyingActivitiesInd
Subject To Proxy Tax	false	SubjectToProxyTaxInd
Donor Advised Fund	false	DonorAdvisedFundInd
Conservation Easements	false	ConservationEasementsInd
Collections Of Art	Yes (true)	CollectionsOfArtInd
Credit Counseling	false	CreditCounselingInd
Temp Or Permanent Endowments	Yes (true)	TempOrPermanentEndowmentsInd
Report Land Building Equipment	Yes (true)	ReportLandBuildingEquipmentInd
Report Investments Other Sec	false	ReportInvestmentsOtherSecInd
Report Program Related Invst	false	ReportProgramRelatedInvstInd
Report Other Assets	false	ReportOtherAssetsInd
Report Other Liabilities	Yes (true)	ReportOtherLiabilitiesInd
Include FIN48 Footnote	Yes (true)	IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt	Yes (true)	IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt	false	ConsolidatedAuditFinclStmtInd
School Operating	false	SchoolOperatingInd
Foreign Office	Yes (true)	ForeignOfficeInd
Foreign Activities	Yes (true)	ForeignActivitiesInd
More Than5000 K To Org	Yes (true)	MoreThan5000KToOrgInd
More Than5000 K To Individuals	false	MoreThan5000KToIndividualsInd
Professional Fundraising	Yes (true)	ProfessionalFundraisingInd
Fundraising Activities	Yes (true)	FundraisingActivitiesInd
Gaming Activities	false	GamingActivitiesInd
Operate Hospital	false	OperateHospitalInd
Grants To Organizations	Yes (true)	GrantsToOrganizationsInd
Grants To Individuals	false	GrantsToIndividualsInd
Schedule J Required	Yes (true)	ScheduleJRequiredInd
Tax Exempt Bonds	false	TaxExemptBondsInd
Engaged In Excess Benefit Trans	false	EngagedInExcessBenefitTransInd
PY Excess Benefit Trans	false	PYExcessBenefitTransInd
Loan Outstanding	false	LoanOutstandingInd
Grant To Related Person	false	GrantToRelatedPersonInd
Business Rln With Org Mem	false	BusinessRlnWithOrgMemInd
Business Rln With Fam Mem	false	BusinessRlnWithFamMemInd
Business Rln With Officer Ent	false	BusinessRlnWithOfficerEntInd
Deductible Non Cash Contri	Yes (true)	DeductibleNonCashContriInd
Deductible Art Contribution	false	DeductibleArtContributionInd
Terminate Operations	false	TerminateOperationsInd
Partial Liquidation	false	PartialLiquidationInd
Disregarded Entity	false	DisregardedEntityInd
Related Entity	false	RelatedEntityInd
Related Organization Ctrl Ent	false	RelatedOrganizationCtrlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org	false	TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp	false	ActivitiesConductedPrtshpInd
Schedule O Required	Yes (true)	ScheduleORequiredInd
IRP Document	124	IRPDocumentCnt
IRP Document W2 G	0	IRPDocumentW2GCnt
Backup Wthld Compliance	Yes (true)	BackupWthldComplianceInd
Employee	94	EmployeeCnt
Employment Tax Returns Filed	Yes (true)	EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit	false	UnrelatedBusIncmOverLimitInd
Foreign Financial Account	Yes (true)	ForeignFinancialAccountInd
Foreign Country	TH	ForeignCountryCd
Prohibited Tax Shelter Trans	false	ProhibitedTaxShelterTransInd
Taxable Party Notification	false	TaxablePartyNotificationInd
Nondeductible Contributions	false	NondeductibleContributionsInd
Quid Pro Quo Contributions	Yes (true)	QuidProQuoContributionsInd
Quid Pro Quo Contri Discl	Yes (true)	QuidProQuoContriDisclInd
Form8282 Property Disposed Of	false	Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct	false	RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct	false	PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services	false	IndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht Pymt	false	SubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst Inc	false	SubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VI	Yes (X)	InfoInScheduleOPartVIInd
Governing Body Voting Members	12	GoverningBodyVotingMembersCnt
Independent Voting Member	12	IndependentVotingMemberCnt
Family Or Business Rln	false	FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties	false	DelegationOfMgmtDutiesInd
Change To Org Documents	false	ChangeToOrgDocumentsInd
Material Diversion Or Misuse	false	MaterialDiversionOrMisuseInd
Members Or Stockholders	false	MembersOrStockholdersInd
Election Of Board Members	false	ElectionOfBoardMembersInd
Decisions Subject To Approva	false	DecisionsSubjectToApprovaInd
Minutes Of Governing Body	Yes (true)	MinutesOfGoverningBodyInd
Minutes Of Committees	Yes (true)	MinutesOfCommitteesInd
Officer Mailing Address	false	OfficerMailingAddressInd
Local Chapters	false	LocalChaptersInd
Form990 Provided To Gvrn Body	Yes (true)	Form990ProvidedToGvrnBodyInd
Conflict Of Interest Policy	Yes (true)	ConflictOfInterestPolicyInd
Annual Disclosure Covered Prsn	Yes (true)	AnnualDisclosureCoveredPrsnInd
Regular Monitoring Enfrc	Yes (true)	RegularMonitoringEnfrcInd
Whistleblower Policy	Yes (true)	WhistleblowerPolicyInd
Document Retention Policy	Yes (true)	DocumentRetentionPolicyInd
Compensation Process CEO	Yes (true)	CompensationProcessCEOInd
Compensation Process Other	Yes (true)	CompensationProcessOtherInd
Investment In Joint Venture	false	InvestmentInJointVentureInd
States Where Copy Of Return Is Fld	AL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	FL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	GA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	HI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	IL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MD	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NJ	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NM	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	PA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	RI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	SC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	TN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	UT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	VA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WV	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WI	StatesWhereCopyOfReturnIsFldCd
Own Website	Yes (X)	OwnWebsiteInd
Upon Request	Yes (X)	UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Field	Value	IRS element (for citing)
Person	BRADLEY JENSEN	PersonNm
Phone	2128061703	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	120 WALL STREET 13TH FLOOR	AddressLine1Txt
City	NEW YORK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	100053908	ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (29 entries)

TitleTitleTxt	Average Hours Per WeekAverageHoursPerWeekRt	Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt	Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd	OfficerOfficerInd	Reportable Comp From OrgReportableCompFromOrgAmt	Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt	Other CompensationOtherCompensationAmt	Key EmployeeKeyEmployeeInd	Highest Compensated EmployeeHighestCompensatedEmployeeInd
Bill Roedy
Chairman of the Board	1.0	0.0	Yes (X)	Yes (X)	$0	$0	$0
Cindy Rachofsky
Vice Chairman	1.0	0.0	Yes (X)	Yes (X)	$0	$0	$0
Arlen H Andelson
Secretary	1.0	0.0	Yes (X)	Yes (X)	$0	$0	$0
Raymond F Schinazi PhD
Treasurer (As of 03/19)	1.0	0.0	Yes (X)	Yes (X)	$0	$0	$0
Michael J Klingensmith
Treasurer (Thru 03/19)	1.0	0.0	Yes (X)	Yes (X)	$0	$0	$0
David Bohnett
Trustee	1.0	0.0	Yes (X)		$0	$0	$0
Zev Braun
Trustee (NON-VOTING)	1.0	0.0	Yes (X)		$0	$0	$0
Jonathan S Canno
Trustee (Thru 02/19)	1.0	0.0	Yes (X)		$0	$0	$0
Jay Ellis
Trustee	1.0	0.0	Yes (X)		$0	$0	$0
Aileen Getty
Trustee	1.0	0.0	Yes (X)		$0	$0	$0
T Ryan Greenwalt
Trustee (as of 2/19)	1.0	0.0	Yes (X)		$0	$0	$0
Michele V McNeill PharmD
Trustee (NON-VOTING)	1.0	0.0	Yes (X)		$0	$0	$0
Edward Milstein
Trustee	1.0	0.0	Yes (X)		$0	$0	$0
Alan D Schwartz
Trustee	1.0	0.0	Yes (X)		$0	$0	$0
Mario Stevenson
Trustee	1.0	0.0	Yes (X)		$0	$0	$0
Phill Wilson
Trustee (as of 2/19)	1.0	0.0	Yes (X)		$0	$0	$0
Kevin Frost
Chief Executive Officer	40.0	0.0		Yes (X)	$480,408	$0	$93,432
Bradley Jensen
Assistant Treasurer, CFO	40.0	0.0		Yes (X)	$268,290	$0	$62,167
Rowena Johnston
ASST SEC, VP, RESEARCH	40.0	0.0		Yes (X)	$207,188	$0	$32,709
Edward Donnelly
Asst Treasurer, Controller	40.0	0.0		Yes (X)	$165,914	$0	$33,007
Eric Muscatell
Vice President of Development	40.0	0.0			$219,278	$0	$34,529	Yes (X)
Annette Sohn
Vice President, TREAT Asia PGM	40.0	0.0			$235,284	$0	$25,131	Yes (X)
AnnMarie Shannahan
Vice President, Public Info.	40.0	0.0			$237,680	$0	$45,538	Yes (X)
Gregorio Millet
Vice President, Public Policy	40.0	0.0			$186,211	$0	$56,072	Yes (X)
Andrew McInness
Director, Publications	40.0	0.0			$170,102	$0	$67,984		Yes (X)
Anthony Ancona
Vice President, Human Resource	40.0	0.0			$192,931	$0	$31,716		Yes (X)
Susan Doster
Chief Technology Officer	40.0	0.0			$149,888	$0	$52,030		Yes (X)
JONATHAN KEY
DIRECTOR, PHILANTHROPY	40.0	0.0			$193,887	$0	$57,103		Yes (X)
Sebastian Gheith
Associate Counsel	40.0	0.0			$169,030	$0	$67,978		Yes (X)

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	$2,876,091	TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org	$0	TotReportableCompRltdOrgAmt
Total Other Compensation	$659,396	TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K	28	IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed	false	FormerOfcrEmployeesListedInd
Total Comp Greater Than150 K	Yes (true)	TotalCompGreaterThan150KInd
Compensation From Other Srcs	false	CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1Txt	CityContractorAddress/USAddress/CityNm	State AbbreviationContractorAddress/USAddress/StateAbbreviationCd	ZIPContractorAddress/USAddress/ZIPCd	ServicesServicesDesc	CompensationCompensationAmt
AAB PRODUCTION INC
64 ALLEN ROAD 5TH FLOOR	NEW YORK	NY	10002	Events Production	$623,887
PATTERSON BELKNAP WEBB TYLER LLP
1133 Avenue of the Americas	NEW YORK	NY	100366710	LEGAL SERVICES	$512,837
JOSH WOODS PRODUCTION
39 WEST 14TH STREET SUITE 504	NEW YORK	NY	10011	Events Production	$315,500
EIDOLON COMMUNICATIONS INC
15 MAIDEN LANE SUITE 1401	NEW YORK	NY	10038	DIRECT MAIL/CONSULT.	$286,181
INCA INTERNATIONAL PRODUCTIONS INC
40 WORTH STREET SUITE 827	NEW YORK	NY	10013	Events Production	$284,783

Field	Value	IRS element (for citing)
Cntrct Rcvd Greater Than100 K	13	CntrctRcvdGreaterThan100KCnt
Federated Campaigns	$90,281	FederatedCampaignsAmt
Fundraising	$27,896,470	FundraisingAmt
Government Grants	$6,017,798	GovernmentGrantsAmt
All Other Contributions	$6,271,154	AllOtherContributionsAmt
Noncash Contributions	$63,158	NoncashContributionsAmt
Total Contributions	$40,275,703	TotalContributionsAmt
Total Program Service Revenue	$0	TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$1,492,677	TotalRevenueColumnAmt
Exclusion	$1,492,677	ExclusionAmt

Incm From Invest Bond Proceeds IncmFromInvestBondProceedsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Royalties Revenue RoyaltiesRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$45,654	TotalRevenueColumnAmt
Exclusion	$45,654	ExclusionAmt

Rental Income Or Loss RentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Real	$0	RealAmt
Personal	$0	PersonalAmt

Net Rental Income Or Loss NetRentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

Field	Value	IRS element (for citing)
Securities	$23,533,474	SecuritiesAmt
Other	$1,455	OtherAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

Field	Value	IRS element (for citing)
Securities	$22,764,663	SecuritiesAmt

Gain Or Loss GainOrLossGrp

Field	Value	IRS element (for citing)
Securities	$768,811	SecuritiesAmt
Other	$1,455	OtherAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$770,266	TotalRevenueColumnAmt
Exclusion	$770,266	ExclusionAmt

Field	Value	IRS element (for citing)
Fundraising Gross Income	$1,794,170	FundraisingGrossIncomeAmt
Contri Rpt Fundraising Event	$27,896,470	ContriRptFundraisingEventAmt
Fundraising Direct Expenses	$13,056,389	FundraisingDirectExpensesAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

Field	Value	IRS element (for citing)
Total Revenue Column	-$11,262,219	TotalRevenueColumnAmt
Exclusion	-$11,262,219	ExclusionAmt

Field	Value	IRS element (for citing)
Gaming Gross Income	$0	GamingGrossIncomeAmt
Gaming Direct Expenses	$0	GamingDirectExpensesAmt

Net Income From Gaming NetIncomeFromGamingGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Field	Value	IRS element (for citing)
Gross Sales Of Inventory	$25,294	GrossSalesOfInventoryAmt
Cost Of Goods Sold	$9,281	CostOfGoodsSoldAmt

Net Income Or Loss NetIncomeOrLossGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$16,013	TotalRevenueColumnAmt
Exclusion	$16,013	ExclusionAmt

Other Revenue Misc OtherRevenueMiscGrp (3 entries)

DescDesc	BusinessBusinessCd	Total Revenue ColumnTotalRevenueColumnAmt	ExclusionExclusionAmt
STORE SALES	900099	$1,859	$1,859
LIST RENTALS	900099	$170	$170
MISCELLANEOUS INCOME	900099	$1,267	$1,267

Field	Value	IRS element (for citing)
Other Revenue Total	$3,296	OtherRevenueTotalAmt

Total Revenue TotalRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$31,341,390	TotalRevenueColumnAmt
Exclusion	-$8,934,313	ExclusionAmt

Field	Value	IRS element (for citing)
Info In Schedule O Part IX	Yes (X)	InfoInScheduleOPartIXInd

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

Field	Value	IRS element (for citing)
Total	$6,879,084	TotalAmt
Program Services	$6,879,084	ProgramServicesAmt

Grants To Domestic Individuals GrantsToDomesticIndividualsGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Foreign Grants ForeignGrantsGrp

Field	Value	IRS element (for citing)
Total	$3,230,668	TotalAmt
Program Services	$3,230,668	ProgramServicesAmt

Benefits To Members BenefitsToMembersGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

Field	Value	IRS element (for citing)
Total	$2,522,218	TotalAmt
Program Services	$1,837,955	ProgramServicesAmt
Management And General	$326,246	ManagementAndGeneralAmt
Fundraising	$358,017	FundraisingAmt

Comp Disqual Persons CompDisqualPersonsGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

Field	Value	IRS element (for citing)
Total	$6,087,863	TotalAmt
Program Services	$4,025,651	ProgramServicesAmt
Management And General	$676,870	ManagementAndGeneralAmt
Fundraising	$1,385,342	FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

Field	Value	IRS element (for citing)
Total	$378,518	TotalAmt
Program Services	$247,419	ProgramServicesAmt
Management And General	$43,798	ManagementAndGeneralAmt
Fundraising	$87,301	FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

Field	Value	IRS element (for citing)
Total	$1,637,261	TotalAmt
Program Services	$1,057,777	ProgramServicesAmt
Management And General	$229,336	ManagementAndGeneralAmt
Fundraising	$350,148	FundraisingAmt

Payroll Taxes PayrollTaxesGrp

Field	Value	IRS element (for citing)
Total	$520,459	TotalAmt
Program Services	$336,756	ProgramServicesAmt
Management And General	$65,216	ManagementAndGeneralAmt
Fundraising	$118,487	FundraisingAmt

Fees For Services Management FeesForServicesManagementGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Fees For Services Legal FeesForServicesLegalGrp

Field	Value	IRS element (for citing)
Total	-$4,808	TotalAmt
Program Services	-$9,150	ProgramServicesAmt
Management And General	$4,324	ManagementAndGeneralAmt
Fundraising	$18	FundraisingAmt

Fees For Services Accounting FeesForServicesAccountingGrp

Field	Value	IRS element (for citing)
Total	$196,725	TotalAmt
Management And General	$196,725	ManagementAndGeneralAmt

Fees For Services Lobbying FeesForServicesLobbyingGrp

Field	Value	IRS element (for citing)
Total	$123,466	TotalAmt
Program Services	$123,466	ProgramServicesAmt

Fees For Services Prof Fundraising FeesForServicesProfFundraising

Field	Value	IRS element (for citing)
Total	$747,847	TotalAmt
Fundraising	$747,847	FundraisingAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

Field	Value	IRS element (for citing)
Total	$277,449	TotalAmt
Management And General	$277,449	ManagementAndGeneralAmt

Fees For Services Other FeesForServicesOtherGrp

Field	Value	IRS element (for citing)
Total	$1,366,933	TotalAmt
Program Services	$907,234	ProgramServicesAmt
Management And General	$34,283	ManagementAndGeneralAmt
Fundraising	$425,416	FundraisingAmt

Advertising AdvertisingGrp

Field	Value	IRS element (for citing)
Total	$346,932	TotalAmt
Program Services	$309,763	ProgramServicesAmt
Management And General	$1,993	ManagementAndGeneralAmt
Fundraising	$35,176	FundraisingAmt

Office Expenses OfficeExpensesGrp

Field	Value	IRS element (for citing)
Total	$68,296	TotalAmt
Program Services	$41,715	ProgramServicesAmt
Management And General	$7,387	ManagementAndGeneralAmt
Fundraising	$19,194	FundraisingAmt

Information Technology InformationTechnologyGrp

Field	Value	IRS element (for citing)
Total	$205,549	TotalAmt
Program Services	$155,635	ProgramServicesAmt
Management And General	$21,016	ManagementAndGeneralAmt
Fundraising	$28,898	FundraisingAmt

Royalties RoyaltiesGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Occupancy OccupancyGrp

Field	Value	IRS element (for citing)
Total	$1,517,346	TotalAmt
Program Services	$1,086,453	ProgramServicesAmt
Management And General	$171,818	ManagementAndGeneralAmt
Fundraising	$259,075	FundraisingAmt

Travel TravelGrp

Field	Value	IRS element (for citing)
Total	$1,236,674	TotalAmt
Program Services	$476,254	ProgramServicesAmt
Management And General	$2,221	ManagementAndGeneralAmt
Fundraising	$758,199	FundraisingAmt

Pymt Travel Entrtnmnt Pub Ofcl PymtTravelEntrtnmntPubOfclGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Conferences Meetings ConferencesMeetingsGrp

Field	Value	IRS element (for citing)
Total	$510,065	TotalAmt
Program Services	$493,801	ProgramServicesAmt
Management And General	$4,190	ManagementAndGeneralAmt
Fundraising	$12,074	FundraisingAmt

Interest InterestGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Payments To Affiliates PaymentsToAffiliatesGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Depreciation Depletion DepreciationDepletionGrp

Field	Value	IRS element (for citing)
Total	$446,165	TotalAmt
Program Services	$324,244	ProgramServicesAmt
Management And General	$51,322	ManagementAndGeneralAmt
Fundraising	$70,599	FundraisingAmt

Insurance InsuranceGrp

Field	Value	IRS element (for citing)
Total	$364,337	TotalAmt
Program Services	$264,776	ProgramServicesAmt
Management And General	$41,910	ManagementAndGeneralAmt
Fundraising	$57,651	FundraisingAmt

Other Expenses OtherExpensesGrp (4 entries)

DescDesc	TotalTotalAmt	Program ServicesProgramServicesAmt	Management And GeneralManagementAndGeneralAmt	FundraisingFundraisingAmt
PROGRAM MATERIALS	$2,230,607	$2,230,607
PROGRAM TECHNICAL SUPPORT	$836,863	$836,863
BAD DEBT EXPENSE	$631,150	$458,679	$72,601	$99,870
PRINTING	$550,024	$121,353	$1,072	$427,599

All Other Expenses AllOtherExpensesGrp

Field	Value	IRS element (for citing)
Total	$2,064,513	TotalAmt
Program Services	$988,794	ProgramServicesAmt
Management And General	$493,180	ManagementAndGeneralAmt
Fundraising	$582,539	FundraisingAmt

Total Functional Expenses TotalFunctionalExpensesGrp

Field	Value	IRS element (for citing)
Total	$34,972,204	TotalAmt
Program Services	$26,425,797	ProgramServicesAmt
Management And General	$2,722,957	ManagementAndGeneralAmt
Fundraising	$5,823,450	FundraisingAmt

Field	Value	IRS element (for citing)
Joint Costs	Yes (X)	JointCostsInd

Total Joint Costs TotalJointCostsGrp

Field	Value	IRS element (for citing)
Total	$518,072	TotalAmt
Program Services	$156,353	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$361,719	FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

Field	Value	IRS element (for citing)
BOY	$5,477,346	BOYAmt
EOY	$6,826,913	EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

Field	Value	IRS element (for citing)
BOY	$691,606	BOYAmt
EOY	$1,423,450	EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$699,100	BOYAmt
EOY	$867,952	EOYAmt

Accounts Receivable AccountsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$6,388,976	BOYAmt
EOY	$6,339,168	EOYAmt

Receivables From Officers Etc ReceivablesFromOfficersEtcGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Rcvbl From Disqualified Prsn RcvblFromDisqualifiedPrsnGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Oth Notes Loans Receivable Net OthNotesLoansReceivableNetGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Inventories For Sale Or Use InventoriesForSaleOrUseGrp

Field	Value	IRS element (for citing)
BOY	$425,761	BOYAmt
EOY	$413,307	EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

Field	Value	IRS element (for citing)
BOY	$1,960,938	BOYAmt
EOY	$2,003,877	EOYAmt

Field	Value	IRS element (for citing)
Land Bldg Equip Cost Or Other Bss	$7,298,048	LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec	$4,497,236	LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

Field	Value	IRS element (for citing)
BOY	$2,921,534	BOYAmt
EOY	$2,800,812	EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

Field	Value	IRS element (for citing)
BOY	$48,872,134	BOYAmt
EOY	$42,758,997	EOYAmt

Investments Other Securities InvestmentsOtherSecuritiesGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Investments Program Related InvestmentsProgramRelatedGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Intangible Assets IntangibleAssetsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Other Assets Total OtherAssetsTotalGrp

Field	Value	IRS element (for citing)
BOY	$2,098,741	BOYAmt
EOY	$722,627	EOYAmt

Total Assets TotalAssetsGrp

Field	Value	IRS element (for citing)
BOY	$69,536,136	BOYAmt
EOY	$64,157,103	EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

Field	Value	IRS element (for citing)
BOY	$3,655,122	BOYAmt
EOY	$2,769,299	EOYAmt

Grants Payable GrantsPayableGrp

Field	Value	IRS element (for citing)
BOY	$2,768,840	BOYAmt
EOY	$2,086,068	EOYAmt

Deferred Revenue DeferredRevenueGrp

Field	Value	IRS element (for citing)
BOY	$8,596,427	BOYAmt
EOY	$7,947,789	EOYAmt

Tax Exempt Bond Liabilities TaxExemptBondLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Escrow Account Liability EscrowAccountLiabilityGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Loans From Officers Directors LoansFromOfficersDirectorsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Unsecured Notes Loans Payable UnsecuredNotesLoansPayableGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Other Liabilities OtherLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$1,965,068	BOYAmt
EOY	$1,869,386	EOYAmt

Total Liabilities TotalLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$16,985,457	BOYAmt
EOY	$14,672,542	EOYAmt

Field	Value	IRS element (for citing)
Organization Follows SFAS117	Yes (X)	OrganizationFollowsSFAS117Ind

Unrestricted Net Assets UnrestrictedNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$48,668,968	BOYAmt
EOY	$45,254,909	EOYAmt

Temporarily Rstr Net Assets TemporarilyRstrNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$3,509,128	BOYAmt
EOY	$3,850,319	EOYAmt

Permanently Rstr Net Assets PermanentlyRstrNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$372,583	BOYAmt
EOY	$379,333	EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$52,550,679	BOYAmt
EOY	$49,484,561	EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$69,536,136	BOYAmt
EOY	$64,157,103	EOYAmt

Field	Value	IRS element (for citing)
Reconcilation Revenue Expnss	-$3,630,814	ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst	$564,696	NetUnrlzdGainsLossesInvstAmt
Method Of Accounting Accrual	Yes (X)	MethodOfAccountingAccrualInd
Accountant Compile Or Review	false	AccountantCompileOrReviewInd
FS Audited	Yes (true)	FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

Field	Value	IRS element (for citing)
Separate Basis Fincl Stmt	Yes (X)	SeparateBasisFinclStmtInd

Field	Value	IRS element (for citing)
Audit Committee	Yes (true)	AuditCommitteeInd
Federal Grant Audit Required	Yes (true)	FederalGrantAuditRequiredInd
Federal Grant Audit Performed	Yes (true)	FederalGrantAuditPerformedInd

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Public Organization170	Yes (X)	PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$56,251,128	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$58,810,206	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$50,842,378	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$42,784,390	CurrentTaxYearMinus1YearAmt
Current Tax Year	$40,275,703	CurrentTaxYearAmt
Total	$248,963,805	TotalAmt

Tax Rev Levied Orgnztnl Bnft170 TaxRevLeviedOrgnztnlBnft170Grp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Govt Furn Srvc Fclts Vl170 GovtFurnSrvcFcltsVl170Grp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$56,251,128	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$58,810,206	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$50,842,378	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$42,784,390	CurrentTaxYearMinus1YearAmt
Current Tax Year	$40,275,703	CurrentTaxYearAmt
Total	$248,963,805	TotalAmt

Field	Value	IRS element (for citing)
Substantial Contributors Tot	$0	SubstantialContributorsTotAmt
Public Support Total170	$248,963,805	PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$1,652,775	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$1,316,372	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$1,354,513	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$1,590,672	CurrentTaxYearMinus1YearAmt
Current Tax Year	$1,538,331	CurrentTaxYearAmt
Total	$7,452,663	TotalAmt

Unrelated Business Net Incm170 UnrelatedBusinessNetIncm170Grp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Other Income170 OtherIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$2,103,589	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$2,246,081	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$1,819,001	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$2,097,498	CurrentTaxYearMinus1YearAmt
Current Tax Year	$1,822,760	CurrentTaxYearAmt
Total	$10,088,929	TotalAmt

Field	Value	IRS element (for citing)
Total Support	$266,505,397	TotalSupportAmt
Public Support CY170	0.93418	PublicSupportCY170Pct
Public Support PY170	0.93335	PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170	Yes (X)	ThirtyThrPctSuprtTestsCY170Ind

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

Field	Value	IRS element (for citing)
Contributor	RESTRICTED	ContributorNum

Contributor Business Name ContributorBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor US Address ContributorUSAddress

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Total Contributions	RESTRICTED	TotalContributionsAmt

Schedule C IRS990ScheduleC

Field	Value	IRS element (for citing)
Total Grassroots Lobbying		TotalGrassrootsLobbyingGrp
Total Direct Lobbying		TotalDirectLobbyingGrp
Total Lobbying Expend		TotalLobbyingExpendGrp
Other Exempt Purpose Expend		OtherExemptPurposeExpendGrp
Total Exempt Purpose Expend		TotalExemptPurposeExpendGrp
Lobbying Nontaxable Amount		LobbyingNontaxableAmountGrp
Grassroots Nontaxable		GrassrootsNontaxableGrp
Tot Lbbyng Grassroot Mns Non Tx		TotLbbyngGrassrootMnsNonTxGrp
Tot Lbby Expend Mns Lbbyng Non Tx		TotLbbyExpendMnsLbbyngNonTxGrp
Volunteers	false	VolunteersInd
Paid Staff Or Management	Yes (true)	PaidStaffOrManagementInd
Media Advertisements	false	MediaAdvertisementsInd
Mailings Members	false	MailingsMembersInd
Publications Or Broadcast	false	PublicationsOrBroadcastInd
Grants Other Organizations	false	GrantsOtherOrganizationsInd
Direct Contact Legislators	false	DirectContactLegislatorsInd
Rallies Demonstrations	false	RalliesDemonstrationsInd
Other Activities	Yes (true)	OtherActivitiesInd
Other Activities	$391,838	OtherActivitiesAmt
Total Lobbying Expenditures	$391,838	TotalLobbyingExpendituresAmt
Not Described Section501c3	false	NotDescribedSection501c3Ind
Form4720 Filed4912 Tax	false	Form4720Filed4912TaxInd

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	LOBBYING EXPENSES	FormAndLineReferenceDesc
Explanation	PART II-B THE FOUNDATION FOR AIDS RESEARCH DEVELOPED AN ACTION AGENDA TO END AIDS THAT IDENTIFIED CRITICAL DECISIONS THAT NEED TO BE MADE TO ADVANCE EVIDENCE BASED AIDS POLICIES. WE CREATED A VARIETY OF ISSUE BRIEFS ON TOPICS SUCH AS THE POTENTIAL IMPACT OF VARIOUS BUDGET SCENARIOS ON GLOBAL HEALTH SERVICES, AND POLICY PRIORITIES TO ADDRESS THE HIV EPIDEMIC AMONG GAY MEN IN THE US. THESE ISSUE BRIEFS WERE SHARED WITH CAPITOL HILL STAFF AND MEMBERS OF THE ADMINISTRATION. AMFAR MET REGULARLY WITH STAFF TO MEMBERS OF CONGRESS AND WITH ADMINISTRATION STAFF, AND WE PROVIDED INPUT TO THE ADMINISTRATION ON DEVELOPMENT OF THE PEPFAR BLUEPRINT FOR AN AIDS FREE GENERATION. AMFAR SPONSORED SEVERAL BRIEFINGS ON CAPITOL HILL ON AIDS POLICY AND RESEARCH ISSUES. AMFAR USES THESE BRIEFINGS AS AN EDUCATIONAL TOOL. The Foundation engaged an independent consultant to engage in lobbying activities on its behalf. Fees paid to this consultant totaled $123,466 in the fiscal year ending September 30, 2019.	ExplanationTxt

Schedule D IRS990ScheduleD

Art Public Exhibition Amounts ArtPublicExhibitionAmountsGrp

Field	Value	IRS element (for citing)
Assets Included	$459,230	AssetsIncludedAmt

Field	Value	IRS element (for citing)
Held Works Art		HeldWorksArtGrp

Collection Used Other Purposes CollectionUsedOtherPurposesGrp

Field	Value	IRS element (for citing)
Collection Used Other Purposes	Yes (X)	CollectionUsedOtherPurposesInd
Other Purposes	Donated Items, Inventory etc.	OtherPurposesDesc

Field	Value	IRS element (for citing)
Solicited Assets Sale	Yes (true)	SolicitedAssetsSaleInd

CY Endwmt Fund CYEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$684,111	BeginningYearBalanceAmt
Contributions	$6,750	ContributionsAmt
Investment Earnings Or Losses	$10,507	InvestmentEarningsOrLossesAmt
End Year Balance	$701,368	EndYearBalanceAmt

CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$593,133	BeginningYearBalanceAmt
Contributions	$4,100	ContributionsAmt
Investment Earnings Or Losses	$86,877	InvestmentEarningsOrLossesAmt
End Year Balance	$684,110	EndYearBalanceAmt

CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$541,231	BeginningYearBalanceAmt
Contributions	$5,950	ContributionsAmt
Investment Earnings Or Losses	$45,952	InvestmentEarningsOrLossesAmt
End Year Balance	$593,133	EndYearBalanceAmt

CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$493,036	BeginningYearBalanceAmt
Contributions	$7,293	ContributionsAmt
Investment Earnings Or Losses	$40,902	InvestmentEarningsOrLossesAmt
End Year Balance	$541,231	EndYearBalanceAmt

CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$490,979	BeginningYearBalanceAmt
Contributions	$7,998	ContributionsAmt
Investment Earnings Or Losses	-$5,941	InvestmentEarningsOrLossesAmt
End Year Balance	$493,036	EndYearBalanceAmt

Field	Value	IRS element (for citing)
Prmnnt Endowment Balance EOY	0.54080	PrmnntEndowmentBalanceEOYPct
Term Endowment Balance EOY	0.45920	TermEndowmentBalanceEOYPct
Endowments Held Unrelated Org	false	EndowmentsHeldUnrelatedOrgInd
Endowments Held Related Org	false	EndowmentsHeldRelatedOrgInd
Land		LandGrp
Buildings		BuildingsGrp

Leasehold Improvements LeaseholdImprovementsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$2,542,490	OtherCostOrOtherBasisAmt
Depreciation	$585,427	DepreciationAmt
Book Value	$1,957,063	BookValueAmt

Equipment EquipmentGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$304,826	OtherCostOrOtherBasisAmt
Depreciation	$303,430	DepreciationAmt
Book Value	$1,396	BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$4,450,732	OtherCostOrOtherBasisAmt
Depreciation	$3,608,379	DepreciationAmt
Book Value	$842,353	BookValueAmt

Field	Value	IRS element (for citing)
Total Book Value Land Buildings	$2,800,812	TotalBookValueLandBuildingsAmt
Federal Income Tax Liability	$0	FederalIncomeTaxLiabilityAmt

Other Liabilities Org OtherLiabilitiesOrgGrp (2 entries)

DescDesc	AmtAmt
LONG TERM LEASE LIABILITY	$1,572,406
SEC. 457 RETIREMENT LIABILITY	$296,980

Field	Value	IRS element (for citing)
Total Liability	$1,869,386	TotalLiabilityAmt
Footnote Text	Yes (X)	FootnoteTextInd
Total Rev Etc Audited Fincl Stmt	$31,715,076	TotalRevEtcAuditedFinclStmtAmt
Net Unrealized Gains Invst	$564,696	NetUnrealizedGainsInvstAmt
Donated Services And Use Fclts	$87,894	DonatedServicesAndUseFcltsAmt
Other Revenue	-$1,455	OtherRevenueAmt
Revenue Not Reported	$651,135	RevenueNotReportedAmt
Revenue Subtotal	$31,063,941	RevenueSubtotalAmt
Investment Expenses Not Incld	$277,449	InvestmentExpensesNotIncldAmt
Revenue Not Reported Fincl Stmt	$277,449	RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990	$31,341,390	TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt	$34,781,194	TotExpnsEtcAuditedFinclStmtAmt
Donated Services Use Fclts	$87,894	DonatedServicesUseFcltsAmt
Other Expenses Included	-$1,455	OtherExpensesIncludedAmt
Expenses Not Reported	$86,439	ExpensesNotReportedAmt
Expenses Subtotal	$34,694,755	ExpensesSubtotalAmt
Investment Expenses Not Incld2	$277,449	InvestmentExpensesNotIncld2Amt
Expenses Not Rpt Fincl Stmt	$277,449	ExpensesNotRptFinclStmtAmt
Total Expenses Per Form990	$34,972,204	TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail (3 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
ENDOWMENTS	PART V, LINE 4 AMFAR'S ENDOWMENT FUND IS INTENDED TO FUND THE VARIOUS GENERAL RESEARCH PROGRAMS THE ORGANIZATION SPONSORS. Reconciliation of Revenue & Expenses Part XI & Part XII, Line 2d Loss/Gain on Disposal of Fixed Assets $-1,455
FIN 48 - INCOME TAXES	AMFAR FOLLOWS GUIDANCE THAT CLARIFIES THE ACCOUNTING FOR UNCERTAINTY IN TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN, INCLUDING ISSUES RELATING TO FINANCIAL STATEMENT RECOGNITION AND GUIDANCE ON MEASUREMENT. THIS GUIDANCE PROVIDES THAT THE TAX EFFECTS FROM AN UNCERTAIN TAX POSITION CAN ONLY BE RECOGNIZED IN THE FINANCIAL STATEMENTS IF THE POSITION IS "MORE-LIKELY-THAN-NOT" TO BE SUSTAINED IF THE POSITION WERE TO BE CHALLENGED BY A TAXING AUTHORITY. THE ASSESSMENT OF THE TAX POSITION IS BASED SOLELY ON THE TECHNICAL MERITS OF THE POSITION, WITHOUT REGARD TO THE LIKELIHOOD THAT THE TAX POSITION MAY BE CHALLENGED. AMFAR IS EXEMPT FROM FEDERAL INCOME TAX UNDER IRC SECTION 501(C)(3), THOUGH IT IS SUBJECT TO TAX ON INCOME UNRELATED TO ITS EXEMPT PURPOSE, UNLESS THAT INCOME IS OTHERWISE EXCLUDED BY THE CODE. AMFAR HAS PROCESSES PRESENTLY IN PLACE TO ENSURE THE MAINTENANCE OF ITS TAX-EXEMPT STATUS; TO IDENTIFY AND REPORT UNRELATED INCOME; TO DETERMINE ITS FILING AND TAX OBLIGATIONS IN JURISDICTIONS FOR WHICH IT WAS NEXUS; AND TO IDENTIFY AND EVALUATE OTHER MATTERS THAT MAY BE CONSIDERED TAX POSITIONS. AMFAR HAS DETERMINED THAT THERE ARE NO MATERIAL UNCERTAIN TAX POSITIONS THAT REQUIRE RECOGNITION OR DISCLOSURE IN THE FINANCIAL STATEMENTS.
COLLECTIONS OF ART, HISTORICAL TREASURES, OR OTHER SIMILAR ASSETS	PART III, LINE 4 AMFAR HOLDS VARIOUS ITEMS OF JEWELRY, PHOTOGRAPHS AND OTHER ITEMS OF ARTISTIC VALUE THAT HAVE BEEN DONATED TO THE ORGANIZATION FOR SALE AT SPECIAL EVENTS. THE ORGANIZATION HAS MAINTAINED THESE ITEMS IN INVENTORY FOR A FEW YEARS AND IS IN THE PROCESS OF SELLING THEM.

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (true)	GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (9 entries)

RegionRegionTxt	Type Of Activities ConductedTypeOfActivitiesConductedTxt	Specific Services ProvidedSpecificServicesProvidedTxt	Region Total ExpendituresRegionTotalExpendituresAmt	OfficesOfficesCnt	EmployeeEmployeeCnt
East Asia and the Pacific	Grantmaking	n/a	$1,885,978
Europe (Including Iceland and Greenland)	Grantmaking	N/A	$1,031,960
North America	Grantmaking	N/A	$75,000
South Asia	Grantmaking	N/A	$63,568
Sub-Saharan Africa	Grantmaking	N/A	$174,161
East Asia and the Pacific	Program Services	Therapeutics, Training	$1,855,984	1	15
East Asia and the Pacific	Fundraising	N/A	$1,563,509
Europe (Including Iceland and Greenland)	Fundraising	N/A	$8,408,176
South America	Fundraising	N/A	$290,459

Field	Value	IRS element (for citing)
Subtotal Offices	1	SubtotalOfficesCnt
Subtotal Employees	15	SubtotalEmployeesCnt
Total Office	1	TotalOfficeCnt
Total Employee	15	TotalEmployeeCnt
Subtotal Spent	$15,348,795	SubtotalSpentAmt
Total Spent	$15,348,795	TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (82 entries)

RegionRegionTxt	Purpose Of GrantPurposeOfGrantTxt	Cash GrantCashGrantAmt	Manner Of Cash DisbursementMannerOfCashDisbursementTxt	Non Cash AssistanceNonCashAssistanceAmt
East Asia/Pacific	BASIC RESEARCH	$249,961	wire transfe	$0
East Asia/Pacific	BASIC RESEARCH	$24,828	wire transfe	$0
East Asia/Pacific	BASIC RESEARCH	$37,500	wire transfe	$0
East Asia/Pacific	GMT INITIATIVE	$46,153	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$31,251	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$20,848	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$6,245	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$19,995	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$14,925	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$15,450	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$9,861	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$21,208	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$16,700	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$20,490	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$22,686	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$21,688	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$21,582	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$23,528	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$20,993	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$21,236	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$15,570	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$23,212	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$21,368	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$21,228	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$79,383	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$7,500	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$7,350	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$6,450	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$6,150	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$6,600	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$7,500	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$7,425	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$7,500	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$7,500	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$7,500	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$235,373	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$199,262	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$79,357	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$7,500	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$7,500	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$15,000	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$14,988	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$7,500	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$24,500	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$20,000	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$10,705	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$8,110	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$7,154	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$6,156	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$7,928	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$20,357	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$7,820	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$62,732	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$9,242	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$124,794	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$8,999	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$10,400	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$7,900	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$8,000	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$5,832	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$8,000	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$8,000	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$6,500	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$5,625	wire transfe	$0
Europe	BASIC RESEARCH	$73,333	wire transfe	$0
Europe	BASIC RESEARCH	$45,000	wire transfe	$0
Europe	RESEARCH	$141,077	wire transfe	$0
Europe	RESEARCH	$365,143	wire transfe	$0
Europe	RESEARCH	$60,000	wire transfe	$0
Europe	RESEARCH	$429,468	wire transfe	$0
North America (excl USA)	BASIC RESEARCH	$75,000	wire transfe	$0
South Asia	TREAT ASIA	$19,078	wire transfe	$0
South Asia	TREAT ASIA	$19,974	wire transfe	$0
South Asia	TREAT ASIA	$7,500	wire transfe	$0
South Asia	TREAT ASIA	$17,016	wire transfe	$0
Sub-Saharan Africa	BASIC RESEARCH	$24,998	wire transfe	$0
Sub-Saharan Africa	BASIC RESEARCH	$24,698	wire transfe	$0
Sub-Saharan Africa	BASIC RESEARCH	$24,998	wire transfe	$0
Sub-Saharan Africa	PUBLIC POLICY	$30,000	wire transfe	$0
Sub-Saharan Africa	TREAT ASIA	$64,351	wire transfe	$0
Sub-Saharan Africa	TREAT ASIA	$5,041	wire transfe	$0
Sub-Saharan Africa	TREAT ASIA	$7,647	wire transfe	$0

Field	Value	IRS element (for citing)
Total501c3 Org	82	Total501c3OrgCnt
Transfer To Foreign Corp	false	TransferToForeignCorpInd
Interest In Foreign Trust	false	InterestInForeignTrustInd
Foreign Corp Ownership	false	ForeignCorpOwnershipInd
Passive Foreign Investmest Co	false	PassiveForeignInvestmestCoInd
Foreign Partnership	false	ForeignPartnershipInd
Boycott Countries	false	BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (3 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
FOREIGN ACTIVITIES	PART I, LINE 2 INTERNATIONAL ORGANIZATIONS ARE RECOMMENDED FOR FUNDING BASED UPON THE RESULTS OF COMMUNITY-BASED PEER REVIEW AND/OR PROGRAM STAFF ASSESSMENT OF PROPOSAL MERIT AND ORGANIZATION CAPACITY TO UNDERTAKE PROPOSED PROJECTS THAT ARE CHARITABLE IN PURPOSE. PRE-AWARD DUE-DILIGENCE FOR NEW INTERNATIONAL GRANTEES INCLUDES REVIEW OF ORGANIZATION DOCUMENTS AND REGISTRATIONS TO VERIFY THAT THE ORGANIZATION OPERATES FOR A CHARITABLE PURPOSE AND THAT BASIC CAPACITY FOR PROJECT OVERSIGHT AND GOVERNANCE HAS BEEN ESTABLISHED. ALL INTERNATIONAL GRANTEES ARE REQUIRED TO REPORT SEMI-ANNUALLY ON PROJECT PROGRESS AND EXPENDITURES; CONTINUED REPORTING IS REQUIRED UNTIL SUCH TIME AS GRANT FUNDS ARE EXPENDED IN FULL. REPORTS ARE REVIEWED BY ADMINISTRATIVE AND PROGRAM STAFF. ADDITIONAL OVERSIGHT IS PROVIDED AS NECESSARY BY MEANS OF ONGOING, INFORMAL CONTACT WITH SITES REGARDING PROGRESS AND TECHNICAL ISSUES AND SITE VISITS WHERE FEASIBLE. INTERNATIONAL RESEARCH GRANT RECIPIENTS SUBMIT AN INTERIM AND A FINAL PROGRESS REPORTING ADDITION TO EXPENDITURES REPORTS DUE FOLLOWING THE ENDS OF THE 2ND, 3RD AND FINAL QUARTERS OF THE PERFORMANCE PERIOD.
FOREIGN ACTIVITIES	PART I, LINE 3, COLUMN D THE FOUNDATION FOR AIDS RESEARCH CONDUCTS MANY OF ITS GRANT-MAKING PROGRAM SERVICES (SEE PART III OF FORM 990) IN U.S. AND FOREIGN JURISDICTIONS. IN COLUMN D, THE ORGANIZATION HAS REPORTED THE BASIC PROGRAM THESE GRANTS SUPPORT; PLEASE REFER TO PART III FOR MORE INFORMATION ABOUT THESE PROGRAMS/INITIATIVES.
FOREIGN ACTIVITIES - STATUS OF GRANTEES	THE FOUNDATION FOR AIDS RESEARCH SUPPORTS MANY NON-U.S. ORGANIZATIONS IN THE FIGHT AGAINST AIDS AND HIV-RELATED DISEASES. FOR PURPOSES OF SCHEDULE F, PART II, LINE 2 - ALL 82 CHARITIES SUPPORTED ARE PRESUMED TO BE THE EQUIVALENT OF U.S. CHARITIES.

Schedule G IRS990ScheduleG

Field	Value	IRS element (for citing)
Mail Solicitations	Yes (X)	MailSolicitationsInd
Email Solicitations	Yes (X)	EmailSolicitationsInd
Phone Solicitations	Yes (X)	PhoneSolicitationsInd
Solicitation Of Non Govt Grants	Yes (X)	SolicitationOfNonGovtGrantsInd
Solicitation Of Govt Grants	Yes (X)	SolicitationOfGovtGrantsInd
Special Fundraising Events	Yes (X)	SpecialFundraisingEventsInd
Agrmt Prof Fundraising Acty	Yes (true)	AgrmtProfFundraisingActyInd

Fundraiser Activity Info FundraiserActivityInfoGrp (4 entries)

ActivityActivityTxt	Fundraiser Control Of FundsFundraiserControlOfFundsInd	Gross ReceiptsGrossReceiptsAmt	Retained By ContractorRetainedByContractorAmt	Net To OrganizationNetToOrganizationAmt
aab productions INC
events production	false	$20,306,722	$550,543	$19,756,179
Josh Woods Production
events production	false	$3,941,393	$361,400	$3,579,993
EIDOLON COMM INC
direct mail	false	$850,329	$192,503	$657,827
Sanky Comm Inc
direct mail	false	$158,254	$135,463	$22,791

Field	Value	IRS element (for citing)
Total Gross Receipts	$25,256,698	TotalGrossReceiptsAmt
Total Retained By Contractors	$1,239,909	TotalRetainedByContractorsAmt
Total Net To Organization	$24,016,790	TotalNetToOrganizationAmt
Licensed States	AL	LicensedStatesCd
Licensed States	AK	LicensedStatesCd
Licensed States	AR	LicensedStatesCd
Licensed States	CA	LicensedStatesCd
Licensed States	CO	LicensedStatesCd
Licensed States	CT	LicensedStatesCd
Licensed States	DC	LicensedStatesCd
Licensed States	FL	LicensedStatesCd
Licensed States	GA	LicensedStatesCd
Licensed States	HI	LicensedStatesCd
Licensed States	IL	LicensedStatesCd
Licensed States	KS	LicensedStatesCd
Licensed States	KY	LicensedStatesCd
Licensed States	LA	LicensedStatesCd
Licensed States	ME	LicensedStatesCd
Licensed States	MD	LicensedStatesCd
Licensed States	MA	LicensedStatesCd
Licensed States	MI	LicensedStatesCd
Licensed States	MN	LicensedStatesCd
Licensed States	MS	LicensedStatesCd
Licensed States	MO	LicensedStatesCd
Licensed States	NV	LicensedStatesCd
Licensed States	NH	LicensedStatesCd
Licensed States	NJ	LicensedStatesCd
Licensed States	NM	LicensedStatesCd
Licensed States	NY	LicensedStatesCd
Licensed States	NC	LicensedStatesCd
Licensed States	ND	LicensedStatesCd
Licensed States	OH	LicensedStatesCd
Licensed States	OK	LicensedStatesCd
Licensed States	OR	LicensedStatesCd
Licensed States	PA	LicensedStatesCd
Licensed States	RI	LicensedStatesCd
Licensed States	SC	LicensedStatesCd
Licensed States	TN	LicensedStatesCd
Licensed States	TX	LicensedStatesCd
Licensed States	UT	LicensedStatesCd
Licensed States	VA	LicensedStatesCd
Licensed States	WA	LicensedStatesCd
Licensed States	WV	LicensedStatesCd
Licensed States	WI	LicensedStatesCd

Fundraising Event Information FundraisingEventInformationGrp

Field	Value	IRS element (for citing)
Event1	Cannes	Event1Nm
Gross Receipts Event1	$13,695,811	GrossReceiptsEvent1Amt
Charitable Contri Event1	$13,244,311	CharitableContriEvent1Amt
Gross Revenue Event1	$451,500	GrossRevenueEvent1Amt
Rent Facility Costs Event1	$1,071,064	RentFacilityCostsEvent1Amt
Food And Beverage Event1	$382,908	FoodAndBeverageEvent1Amt
Entertainment Event1	$1,832,283	EntertainmentEvent1Amt
Other Direct Expenses Event1	$3,657,242	OtherDirectExpensesEvent1Amt
Event2	Dallas	Event2Nm
Gross Receipts Event2	$5,526,933	GrossReceiptsEvent2Amt
Charitable Contri Event2	$5,324,413	CharitableContriEvent2Amt
Gross Revenue Event2	$202,520	GrossRevenueEvent2Amt
Rent Facility Costs Event2	$257,624	RentFacilityCostsEvent2Amt
Food And Beverage Event2	$226,613	FoodAndBeverageEvent2Amt
Entertainment Event2	$248,752	EntertainmentEvent2Amt
Other Direct Expenses Event2	$801,539	OtherDirectExpensesEvent2Amt
Other Events Total	18	OtherEventsTotalCnt
Gross Receipts Other Events	$10,467,896	GrossReceiptsOtherEventsAmt
Charitable Contri Other Events	$9,327,746	CharitableContriOtherEventsAmt
Gross Revenue Other Events	$1,140,150	GrossRevenueOtherEventsAmt
Rent Fclty Costs Other Events	$442,774	RentFcltyCostsOtherEventsAmt
Food And Beverage Other Events	$730,059	FoodAndBeverageOtherEventsAmt
Entertainment Other Events	$1,559,893	EntertainmentOtherEventsAmt
Oth Direct Expnss Other Events	$1,845,638	OthDirectExpnssOtherEventsAmt
Gross Receipts Total	$29,690,640	GrossReceiptsTotalAmt
Charitable Contributions Tot	$27,896,470	CharitableContributionsTotAmt
Gross Revenue Total Events	$1,794,170	GrossRevenueTotalEventsAmt
Rent Fclty Costs Total Events	$1,771,462	RentFcltyCostsTotalEventsAmt
Food And Beverage Total Events	$1,339,580	FoodAndBeverageTotalEventsAmt
Entertainment Total Events	$3,640,928	EntertainmentTotalEventsAmt
Oth Direct Expnss Total Events	$6,304,419	OthDirectExpnssTotalEventsAmt
Direct Expense Summary Events	$13,056,389	DirectExpenseSummaryEventsAmt
Net Income Summary	-$11,262,219	NetIncomeSummaryAmt

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	SCHEDULE G, PART I	FormAndLineReferenceDesc
Explanation	THE FOUNDATION FOR AIDS RESEARCH ACTUALLY PAID OUT $747,847 IN FUNDRAISING EXPENSES FOR THE YEAR ENDING SEPTEMBER 30, 2019. THIS AMOUNT IS REPORTED ON PART IX, LINE 11(E). FOR PURPOSES OF SCHEDULE G, THE FOUNDATION IS REPORTING ALL AMOUNTS PAID TO THE CONSULTANTS LISTED ON PART I, REGARDLESS OF WHETHER SUCH AMOUNTS WERE PURE FUNDRAISING EXPENSES OR EVENT PRODUCTION COSTS. ON SCHEDULE G, THE TOTAL AMOUNT PAID TO THE ORGANIZATIONS LISTED IS $1,239,909. OF THAT $1,239,909, ONLY $747,847 WAS PAID FOR FUNDRAISING SERVICES, THE REMAINING $492,062 WAS PAID FOR EVENT PRODUCTION SERVICES. IN THE INTERESTS OF CLARITY, THE FOUNDATION WOULD ALSO LIKE TO MAKE CLEAR THAT THE COMPENSATION REPORTED AS HAVING BEEN PAID TO THE PROFESSIONAL FUNDRAISERS REPORTED ON SCHEDULE G IS REPORTED ON A FISCAL YEAR BASIS. SOME OF THOSE SAME FUNDRAISERS ARE REPORTED ON THE FOUNDATION'S TOP 5 HIGHEST PAID INDEPENDENT CONTRACTORS LIST (IN SCHEDULE O). IN COMPLIANCE WITH THE INSTRUCTIONS TO THE FORM 990, COMPENSATION REPORTED FOR PART VII (AND LISTED IN SCHEDULE O) IS REPORTED ON A CALENDAR YEAR BASIS. ACCORDINGLY, AMOUNTS ON PART VII AND SCHEDULE G WILL NOT RECONCILE.	ExplanationTxt

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (true)	GrantRecordsMaintainedInd

Recipient Table RecipientTable (34 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	Recipient EINRecipientEIN	IRC SectionIRCSectionDesc	Cash GrantCashGrantAmt	Non Cash AssistanceNonCashAssistanceAmt	Purpose Of GrantPurposeOfGrantTxt
The Rockefeller University
1230 York Avenue	New York	NY	10065	131624158	501(c)(3)	$13,394	$0	BASIC RESEARCH
Beth Israel Deaconess Medical Center
330 Brookline Avenue	Boston	MA	02215	042103881	501(c)(3)	$213,426	$0	BASIC RESEARCH
Regents of the University of CA San Francisco
3333 California St	San Francisco	CA	94143	946036493	501(c)(3)	$374,968	$0	BASIC RESEARCH
Foundation for the National Inst of Health
9650 Rockville Pike	Bethesda	MD	208143999	521986675	501(c)(3)	$13,334	$0	BASIC RESEARCH
Mayo Clinic College of Medicine
200 First Street SW	Rochester	MN	55905	416011702	501(c)(3)	$42,858	$0	BASIC RESEARCH
Oregon Health and Science University
3181 SW Sam Jackson Park	Portland	OR	97239	931176109	501(c)(3)	$42,848	$0	BASIC RESEARCH
Boston University School of Medicine
650 Albany St EBRC 640	Boston	MA	02118	043314093	501(c)(3)	$75,001	$0	BASIC RESEARCH
Fred Hutchinson Cancer Research Center
1100 Fairview Ave N	Seattle	WA	98109	237156071	501(c)(3)	$68,615	$0	BASIC RESEARCH
University of Maryland at Baltimore
725 Lombard St S615	Baltimore	MD	21201	526002033	501(c)(3)	$60,001	$0	BASIC RESEARCH
Fred Hutchinson Cancer Research Center
1100 Fairview Ave N	Seattle	WA	98109	237156071	501(c)(3)	$42,858	$0	BASIC RESEARCH
International AIDS Vaccine Initiative
125 Broad St 9th Fl	New York	NY	10004	133870223	501(c)(3)	$74,759	$0	BASIC RESEARCH
Weill Medical College of Cornell University
1300 York Avenue	New York	NY	10065	131623978	501(c)(3)	$145,534	$0	BASIC RESEARCH
The Scripps Research Institute
130 Scripps Way	La Jolla	CA	33458	330435954	501(c)(3)	$75,000	$0	BASIC RESEARCH
Emory University
1599 Clifton Rd	Atlanta	GA	303224250	580566256	501(c)(3)	$75,000	$0	BASIC RESEARCH
State University of New York at Buffalo
520 Le Entrance Ste 211	Amherst	NY	14228	916001537	501(c)(3)	$16,666	$0	BASIC RESEARCH
Northwestern University
Searle 6-512 320 E	Chicago	IL	60611	362167817	501(c)(3)	$76,416	$0	BASIC RESEARCH
The Wistar Institute
3601 Spruce Street	Philadelphia	PA	19104	236434390	501(c)(3)	$65,002	$0	BASIC RESEARCH
The Brigham and Women's Hospital Inc
75 Francis Street	Boston	MA	02115	042312909	501(c)(3)	$50,002	$0	BASIC RESEARCH
Harvard Pilgrim Health Care Institute
93 WORCESTER St STE 100	Wellesley	MA	02481	042452600	501(c)(3)	$66,540	$0	BASIC RESEARCH
National Institutes of Health
40 Convent Drive	Bethesda	MD	20892		115	$75,000	$0	BASIC RESEARCH
Johns Hopkins University
733 N BRDWY MRB 117	Baltimore	MD	21205	520595110	501(c)(3)	$102,261	$0	GMT INITIATIVE
Black AIDS Institute
1833 West Eigth 200	Los Angeles	CA	90057	954742741	501(c)(3)	$25,000	$0	PREVENTION SCIENCE OUTREACH
Schwab Charitable Fund
PO Box 628298	Orlando	FL	328628298	311640316	501(c)(3)	$45,000	$0	PREVENTION SCIENCE OUTREACH
Health GAP (Global Access Project)
81 Prospect StREET	Brooklyn	NY	11201	205053765	501(c)(3)	$47,995	$0	PUBLIC POLICY
University of California San Francisco
3333 California St	San Francisco	CA	94143	946036493	501(c)(3)	$3,219,544	$0	RESEARCH
Harvard University
29 Oxford Street	Cambridge	MA	02138	042103580	501(c)(3)	$130,106	$0	RESEARCH
Regents of the University of Minnesota
200 Oak Street	Minneapolis	MN	554552070	416007513	501(c)(3)	$110,096	$0	RESEARCH
University of Washington
4333 Brooklyn Ave	Seattle	WA	981959472	916001537	501(c)(3)	$283,681	$0	RESEARCH
Johns Hopkins University
733 N BRDWY MRB 117	Baltimore	MD	21205	520595110	501(c)(3)	$333,487	$0	RESEARCH
Trustees of the University of Pa
3451 Walnut St	Philadelphia	PA	191046250	231352685	501(c)(3)	$311,171	$0	RESEARCH
Johns Hopkins University
733 N BRDWY MRB 117	Baltimore	MD	21205	520595110	501(c)(3)	$192,460	$0	RESEARCH
The Brigham and Women's Hospital Inc
75 Francis Street	Boston	MA	02115	042312909	501(c)(3)	$50,597	$0	RESEARCH
Johns Hopkins University
733 N BRDWY MRB 117	Baltimore	MD	21205	520595110	501(c)(3)	$178,167	$0	TREAT ASIA
Massachusetts General Hospital
101 Huntington Ave 300	Boston	MA	02199	042697983	501(c)(3)	$30,000	$0	TREAT ASIA

Field	Value	IRS element (for citing)
Total501c3 Org	34	Total501c3OrgCnt

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	GRANTS AND ASSISTANCE	FormAndLineReferenceDesc
Explanation	PART I, LINE 2 AMFAR PROVIDES GRANTS AND FELLOWSHIPS TO INDEPENDENT NOT-FOR-PROFIT ORGANIZATIONS THROUGH A PEER-REVIEW PROCESS. GRANT APPLICATIONS ARE FIRST REVIEWED BY THE FOUNDATION'S VOLUNTEER SCIENTIFIC ADVISORY COMMITTEE, WHICH COMPRISES RECOGNIZED EXPERTS IN THE MEDICAL, SCIENTIFIC, AND SOCIAL SCIENCES DISCIPLINES RELEVANT TO HIV AND AIDS. THE SCIENTIFIC ADVISORY COMMITTEE THEN SENDS ITS EVALUATIONS TO ONE OF THE THREE COMMITTEES (RESEARCH, GLOBAL INITIATIVES OR PUBLIC POLICY) OF THE FOUNDATION'S PROGRAM BOARD, WHICH SERVES IN AN ADVISORY CAPACITY TO THE BOARD OF TRUSTEES. AFTER A PROGRAM COMMITTEE HAS COMPLETED ITS REVIEW OF THE APPLICATIONS, IT PRESENTS ITS FUNDING RECOMMENDATIONS TO AMFAR'S EXECUTIVE COMMITTEE AND/OR THE FULL BOARD OF TRUSTEES FOR FINAL APPROVAL AND FUNDING AUTHORIZATION. GRANTS AND FELLOWSHIPS ARE PAYABLE OVER A ONE-TO-THREE-YEAR PERIOD, AND ARE REVOCABLE AT AMFAR'S OPTION IF THE RECIPIENT'S PERFORMANCE OR USE OF FUNDS IS NOT CONSISTENT WITH THE TERMS OF THE GRANT OR FELLOWSHIPS. IN CERTAIN CASES, THE ACTUAL AMOUNTS PAID UNDER GRANTS AND FELLOWSHIP AWARDS MAY BE LESS THAN THE ORIGINAL AWARD IF THE RECIPIENT DOES NOT USE THE FULL AMOUNT AWARDED. THEREFORE, A RESERVE FOR UNEXPENDED GRANTS AND FELLOWSHIPS HAS BEEN RECORDED. SUBAWARDS ARE GRANTS AWARDED TO NOT-FOR-PROFIT ORGANIZATIONS TO SUPPORT THE COSTS OF COLLABORATION AND PARTICIPATION IN HIV/AIDS-RELATED RESEARCH PROJECTS FOR WHICH AMFAR HAS SECURED RESTRICTED FUNDS. SUBAWARDS ARE PAYABLE OVER A ONE-YEAR PERIOD, ALTHOUGH ADVANCE PAYMENTS, IN FULL OR IN PART, MAY BE ISSUED FOLLOWING EXECUTION OF THE SUBAWARD AGREEMENT. SUBAWARDS ARE CONTINGENT UPON THE AVAILABILITY OF FUNDS AND ARE REVOCABLE IF THE RECIPIENTS' PERFORMANCE OR USE OF FUNDS IS NOT CONSISTENT WITH THE SUBAWARD TERMS.	ExplanationTxt

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Compensation Committee	Yes (X)	CompensationCommitteeInd
Independent Consultant	Yes (X)	IndependentConsultantInd
Compensation Survey	Yes (X)	CompensationSurveyInd
Board Or Committee Approval	Yes (X)	BoardOrCommitteeApprovalInd
Severance Payment	false	SeverancePaymentInd
Supplemental Nonqual Rtr Plan	Yes (true)	SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm	false	EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org	false	CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs	false	CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org	false	CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs	false	CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments	false	AnyNonFixedPaymentsInd
Initial Contract Exception	false	InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (13 entries)

TitleTitleTxt	Base Compensation Filing OrgBaseCompensationFilingOrgAmt	Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt	Bonus Filing OrganizationBonusFilingOrganizationAmount	Bonus Related OrganizationsBonusRelatedOrganizationsAmt	Other Compensation Filing OrgOtherCompensationFilingOrgAmt	Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt	Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt	Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt	Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt	Total Compensation Filing OrgTotalCompensationFilingOrgAmt	Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt	Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
Kevin Frost
Chief Executive Officer	$424,771	$0	$0	$0	$55,637	$0	$37,750	$0	$59,271	$0	$577,429	$0	$0	$0
Bradley Jensen
Assistant Treasurer, CFO	$268,290	$0	$0	$0	$0	$0	$19,104	$0	$43,063	$0	$330,457	$0	$0	$0
Rowena Johnston
ASST SEC, VP, RESEARCH	$207,188	$0	$0	$0	$0	$0	$14,564	$0	$18,145	$0	$239,897	$0	$0	$0
Edward Donnelly
Asst Treasurer, Controller	$165,914	$0	$0	$0	$0	$0	$16,384	$0	$16,623	$0	$198,921	$0	$0	$0
Eric Muscatell
Vice President of Development	$219,278	$0	$0	$0	$0	$0	$16,384	$0	$18,145	$0	$253,807	$0	$0	$0
Annette Sohn
Vice President, TREAT Asia PGM	$235,284	$0	$0	$0	$0	$0	$17,391	$0	$7,740	$0	$260,415	$0	$0	$0
AnnMarie Shannahan
Vice President, Public Info.	$237,680	$0	$0	$0	$0	$0	$16,803	$0	$28,735	$0	$283,218	$0	$0	$0
Gregorio Millet
Vice President, Public Policy	$186,211	$0	$0	$0	$0	$0	$14,109	$0	$41,963	$0	$242,283	$0	$0	$0
Andrew McInness
Director, Publications	$170,102	$0	$0	$0	$0	$0	$12,256	$0	$55,728	$0	$238,086	$0	$0	$0
Anthony Ancona
Vice President, Human Resource	$192,931	$0	$0	$0	$0	$0	$13,571	$0	$18,145	$0	$224,647	$0	$0	$0
Susan Doster
Chief Technology Officer	$149,888	$0	$0	$0	$0	$0	$11,132	$0	$40,898	$0	$201,918	$0	$0	$0
JONATHAN KEY
DIRECTOR, PHILANTHROPY	$193,887	$0	$0	$0	$0	$0	$14,040	$0	$43,063	$0	$250,990	$0	$0	$0
Sebastian Gheith
Associate Counsel	$169,030	$0	$0	$0	$0	$0	$12,250	$0	$55,728	$0	$237,008	$0	$0	$0

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	COMPENSATION	FormAndLineReferenceDesc
Explanation	PART I, LINE 4 CHIEF EXECUTIVE OFFICER, KEVIN FROST, PARTICIPATED IN A SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN. IN CALENDAR YEAR 2018, AMFAR CONTRIBUTED $55,637 INTO MR. FROST'S NON-QUALIFIED RETIREMENT PLAN. THIS AMOUNT IS NOT REPORTED IN SCHEDULE J, PART II, COLUMN (C) BECAUSE THE CONTRIBUTED AMOUNT WAS DISTRIBUTED TO MR. FROST WITHIN THE SAME CALENDAR YEAR. INCLUDED IN SCHEDULE J COLUMN (B)(III) IS MR. FROST'S 2018 EMPLOYER-FUNDED 457(F) CONTRIBUTION OF $55,637.	ExplanationTxt

Schedule M IRS990ScheduleM

Field	Value	IRS element (for citing)
Works Of Art		WorksOfArtGrp
Art Historical Treasures		ArtHistoricalTreasuresGrp
Art Fractional Interest		ArtFractionalInterestGrp
Books And Publications		BooksAndPublicationsGrp
Clothing And Household Goods		ClothingAndHouseholdGoodsGrp
Cars And Other Vehicles		CarsAndOtherVehiclesGrp
Boats And Planes		BoatsAndPlanesGrp
Intellectual Property		IntellectualPropertyGrp

Securities Publicly Traded SecuritiesPubliclyTradedGrp

Field	Value	IRS element (for citing)
Non Cash Checkbox	Yes (X)	NonCashCheckboxInd
Contribution	6	ContributionCnt
Noncash Contributions Rpt F990	$63,158	NoncashContributionsRptF990Amt
Method Of Determining Revenues	sales price	MethodOfDeterminingRevenuesTxt

Field	Value	IRS element (for citing)
Securities Closely Held Stock		SecuritiesCloselyHeldStockGrp
Secur Prtnrshp Trust Intrsts		SecurPrtnrshpTrustIntrstsGrp
Securities Miscellaneous		SecuritiesMiscellaneousGrp
Qualified Contrib Hist Struct		QualifiedContribHistStructGrp
Qualified Contrib Other		QualifiedContribOtherGrp
Real Estate Residential		RealEstateResidentialGrp
Real Estate Commercial		RealEstateCommercialGrp
Real Estate Other		RealEstateOtherGrp
Collectibles		CollectiblesGrp
Food Inventory		FoodInventoryGrp
Drugs And Medical Supplies		DrugsAndMedicalSuppliesGrp
Taxidermy		TaxidermyGrp
Historical Artifacts		HistoricalArtifactsGrp
Scientific Specimens		ScientificSpecimensGrp
Archaeological Artifacts		ArchaeologicalArtifactsGrp
Any Property That Must Be Held	false	AnyPropertyThatMustBeHeldInd
Review Process Unusual NC Gifts	Yes (true)	ReviewProcessUnusualNCGiftsInd
Third Parties Used	false	ThirdPartiesUsedInd

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	FORM 990, SCHEDULE M, LINE 31	FormAndLineReferenceDesc
Explanation	TO THE EXTENT THAT AMFAR RECEIVES NON-STANDARD CONTRIBUTIONS, THE ORGANIZATION'S POLICY IS TO LIQUIDATE THOSE ITEMS INTO CASH FOR EVENTUAL USE IN SUPPORT OF THE ORGANIZATION'S MISSION.	ExplanationTxt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (10 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
PROGRAM SERVICE ACCOMPLISHMENTS (1)	LINE 4A: RESEARCH: AMFAR SUPPORTS RESEARCH PROJECTS THAT EXPLORE NOVEL APPROACHES TO SCIENTIFICALLY SOUND BUT UNTESTED HYPOTHESES IN ALL AREAS OF RESEARCH ON HIV/AIDS, FUNDING GOAL-ORIENTED STUDIES THAT OFTEN LACK THE PRELIMINARY DATA REQUIRED FOR SUPPORT FROM TRADITIONAL GRANT MAKERS. THE FOUNDATION PLAYS A VITAL ROLE IN HIV/AIDS RESEARCH, IDENTIFYING CRITICAL GAPS IN KNOWLEDGE AND PROVIDING ESSENTIAL SEED MONEY THAT ENABLES GRANTEES AND FELLOWS TO TEST THE MERITS OF NEW CONCEPTS OR TECHNOLOGIES THAT SUBSEQUENTLY CAN BE VALIDATED THROUGH LARGE-SCALE STUDIES, SUCH AS THOSE FUNDED BY THE U.S. NATIONAL INSTITUTES OF HEALTH. AMFAR FELLOWSHIPS ALLOW TALENTED YOUNG RESEARCHERS TO CONDUCT ORIGINAL INVESTIGATIONS UNDER THE GUIDANCE OF EXPERIENCED SCIENTISTS, HELPING TO ENSURE THE LONG-TERM VITALITY OF AIDS RESEARCH. NEW GRANTS AND FELLOWSHIPS GRANTS AND FELLOWSHIPS ARE AWARDED THROUGH A RIGOROUS PROCESS OF PEER REVIEW BY A TEAM OF INDEPENDENT HIV/AIDS EXPERTS DRAWN LARGELY FROM THE VOLUNTEER SCIENTISTS ON AMFARS SCIENTIFIC ADVISORY COMMITTEE. GUIDED BY ITS SCIENTIFIC ADVISORS AND WITH THE APPROVAL OF ITS BOARD OF TRUSTEES, AMFAR PURSUES A STRATEGIC RESEARCH PLAN THAT FOCUSES ON THE PURSUIT OF A CURE FOR HIV. COUNTDOWN TO A CURE FOR AIDS IN 2015, AMFAR ANNOUNCED AN INVESTMENT STRATEGY OF UP TO $100 MILLION TO SUPPORT ITS COUNTDOWN TO A CURE FOR AIDS INITIATIVE, WHICH IS AIMED AT DEVELOPING THE SCIENTIFIC BASIS FOR A CURE BY THE END OF 2020. THE STRATEGY REPRESENTS AN UNPRECEDENTED EXPANSION OF AMFARS GRANT MAKING AND IS DESIGNED TO PROVIDE SUPPORT TO ANY SCIENTIST OR TEAM OF INVESTIGATORS FOR ANY RESEARCH IDEA WITH THE POTENTIAL TO ADVANCE THE SEARCH FOR A CURE, AT ANY STAGE OF ITS DEVELOPMENT. IT IS STRUCTURED TO PROVIDE SUSTAINED SUPPORT FOR A WIDE RANGE OF STUDIES THAT ADVANCE BOTH EMERGING AND ESTABLISHED IDEAS. THE STRATEGY COMPRISES THE FOLLOWING COMPONENTS: - AMFAR INSTITUTE FOR HIV CURE RESEARCH ESTABLISHED IN 2015 WITH A $20 MILLION GRANT OVER FIVE YEARS TO THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE INSTITUTE IS THE CORNERSTONE OF AMFARS CURE RESEARCH. - INNOVATION GRANTS THESE TWO-YEAR AWARDS OF UP TO $200,000 EACH ENABLE RESEARCHERS TO TEST INNOVATIVE IDEAS SUPPORTED BY LIMITED PRELIMINARY DATA. - IMPACT GRANTS THESE GRANTS OF UP TO $2 MILLION EACH OVER FOUR YEARS SUPPORT THE IN-DEPTH DEVELOPMENT OF CONCEPTS ALREADY UNDERPINNED BY PRELIMINARY DATA SHOWING GENUINE POTENTIAL FOR ACHIEVING A CURE. - INVESTMENT GRANTS AIMED AT RECRUITING THE EXPERIENCE AND EXPERTISE OF SCIENTISTS FROM OUTSIDE THE FIELD OF HIV, THESE $1 MILLION GRANTS ARE AWARDED OVER A FOUR-YEAR PERIOD. GRANTEES MAY HAVE EXPERTISE IN FIELDS SUCH AS CANCER, NEUROSCIENCE, OR INFLAMMATORY DISEASE THAT CAN DIRECTLY INFORM EFFORTS TO CURE HIV. - ARCHE LAUNCHED IN 2010, THE AMFAR RESEARCH CONSORTIUM ON HIV ERADICATION, OR ARCHE, SUPPORTS COLLABORATIVE TEAMS OF SCIENTISTS IN THE U.S. AND AROUND THE WORLD WORKING ON A RANGE OF HIV CURE STRATEGIES. - OPPORTUNITY FUND THIS FUNDING MECHANISM ENABLES AMFAR TO RESPOND QUICKLY TO EMERGING AND UNFORESEEN RESEARCH OPPORTUNITIES. SINCE LAUNCHING THE COUNTDOWN TO A CURE FOR AIDS INITIATIVE, AMFAR HAS AWARDED 79 COUNTDOWN GRANTS TOTALING MORE THAN $48 MILLION TO SUPPORT RESEARCH CONDUCTED BY 277 SCIENTISTS WORKING AT 95 INSTITUTIONS IN 15 COUNTRIES. IMPACT GRANTS IN SEPTEMBER 2018, AMFAR AWARDED GRANTS TOTALING $828,000 TO ADVANCE TWO CRITICAL AREAS OF HIV CURE RESEARCH. FIVE GRANTS ARE SUPPORTING A RANGE OF EFFORTS TO UNDERSTAND THE MECHANISMS AND PREDICTORS OF POST-TREATMENT CONTROL, WHEREBY A SMALL NUMBER OF INDIVIDUALS ARE ABLE TO CONTROL THEIR HIV AFTER STOPPING TREATMENT. THREE ADDITIONAL GRANTEES ARE STUDYING HIV-POSITIVE POPULATIONS IN LOW- AND MIDDLE-INCOME COUNTRIES TO LOOK FOR DIFFERENCES IN HOW THE PERSISTENT VIRAL RESERVOIR-THE PRINCIPAL BARRIER TO A CUR-FORMS AND CHANGES OVER TIME. IN A COHORT OF POST-TREATMENT CONTROLLERS FROM ONE OF THE LARGEST HIV CLINICAL TRIAL NETWORKS IN THE WORLD, DR. JONATHAN LI OF BRIGHAM AND WOMEN'S HOSPITAL IN BOSTON IS USING NEXT-GENERATION GENOMIC SEQUENCING TO INVESTIGATE WHETHER CHARACTERISTICS OF THE VIRUS OR IMMUNOLOGIC RESPONSES CAN PREDICT POST-TREATMENT CONTROL. ANOTHER GRANTEE, DR. GODWIN NCHINDA, A RESEARCHER IN YAOUNDE, CAMEROON, HAS IDENTIFIED A COHORT OF WOMEN WHO RECEIVED ANTIRETROVIRAL THERAPY (ART) DURING PREGNANCY AND CONTINUE TO CONTROL THEIR VIRUS DESPITE DISCONTINUING TREATMENT AFTER GIVING BIRTH. HE IS STUDYING THIS GROUP TO DETERMINE THE CAUSES OF THEIR VIRAL CONTROL. THE MAJORITY OF WHAT IS KNOWN ABOUT HIV COMES FROM RESEARCH DONE IN HIGH-INCOME COUNTRIES, WHERE HIV SUBTYPE B PREDOMINATES. HOWEVER, SUBTYPE B ACCOUNTS FOR JUST 12% OF GLOBAL HIV INFECTIONS. DR. EDWARD KANKAKA OF THE RAKAI HEALTH SCIENCES PROGRAM IN KAMPALA, UGANDA, HAS SHOWN THAT NON-B HIV-POSITIVE UGANDANS HAD A SMALLER RESERVOIR OF PERSISTENT VIRUS COMPARED TO PEOPLE INFECTED WITH SUBTYPE B. DR. KANKAKA IS EXPANDING THESE STUDIES TO DETERMINE WHETHER FORMATION AND MAINTENANCE OF THE RESERVOIR DIFFER IN THESE POPULATIONS. IN DURBAN, SOUTH AFRICA, DR. ALEX SIGAL IS EXAMINING THE INFLUENCE OF TUBERCULOSIS-A COMMON CO-INFECTION IN LOW- AND MIDDLE-INCOME COUNTRIES-ON THE HIV RESERVOIR. HE IS EXPLORING WHETHER THE IMMUNE RESPONSE TO TB ITSELF ALTERS HIV REACTIVATION-A KEY COMPONENT OF THE "SHOCK AND KILL" APPROACH TO CURING HIV. THE REMAINING GRANTEES ARE DR. MOHAMED ABDEL-MOHSEN OF THE WISTAR INSTITUTE, PHILADELPHIA, PA; DR. JOHN FRATER OF OXFORD UNIVERSITY, UK; DR. REENA RAJASURIAR OF THE UNIVERSITY OF MALAYA, KUALA LUMPUR, MALAYSIA; AND DR. RUI WANG OF HARVARD PILGRIM HEALTHCARE INSTITUTE, WELLESLEY, MA. INVESTMENT GRANTS IN FEBRUARY 2019, AMFAR ANNOUNCED NEW FUNDING TO RESEARCHERS USING CUTTING-EDGE TECHNOLOGY TO ADDRESS THE MAIN BARRIER TO AN HIV CURE: THE PERSISTENT RESERVOIRS OF VIRUS NOT CLEARED BY ART. TOTALING $800,000, THIS NEW ROUND OF INVESTMENT GRANTS LAUNCHED THE CRITICAL THIRD PHASE OF A RESEARCH PROJECTS BEGUN IN 2017. IN THE FIRST TWO PHASES OF HER STUDY, DR. HUI ZHANG OF JOHNS HOPKINS UNIVERSITY USED MASS SPECTROMETRY TO SCAN THE SURFACE OF HUMAN CELLS FOR PROTEINS-BIOMARKERS-THAT DISCRIMINATE BETWEEN LATENTLY INFECTED AND UNINFECTED CELLS. AFTER SCANNING A VARIETY OF CELL LINES, SHE IDENTIFIED 17 POTENTIAL TARGETS. IN PHASE THREE, DR. ZHANG IS TEAMING UP WITH HIV SCIENTIST DR. WEIMING YANG, ALSO OF JOHNS HOPKINS UNIVERSITY, TO DETERMINE IN A PRECLINICAL STUDY WHETHER SPECIFICALLY KILLING CELLS DISPLAYING ANY OF THESE 17 PROTEINS WILL ELIMINATE THE LATENT RESERVOIR. ARCHE (AMFAR RESEARCH CONSORTIUM ON HIV ERADICATION) IN SEPTEMBER 2018, AMFAR AWARDED $800,000 IN NEW FUNDING TO SIX TEAMS OF RESEARCHERS DEVELOPING AN AMBITIOUS GENE THERAPY-BASED APPROACH TO CURING HIV. THE AWARD LAUNCHED A CRITICAL NEW PHASE IN A STUDY INITIATED IN 2017. IN A THREE-PRONGED ATTACK ON THE HIV RESERVOIR, THE RESEARCHERS ARE EMPLOYING BROADLY NEUTRALIZING ANTIBODIES, CAR STEM CELLS-CELLS GENETICALLY REPROGRAMMED TO RECOGNIZE AND ATTACK INFECTED CELLS-AND MOLECULAR SCISSORS TARGETING THE VIRUS. THE GRANT WAS SUPPORTED IN PART BY THE BILL AND MELINDA GATES FOUNDATION. THE INVESTIGATORS ARE: DR. HILDEGARD BNING OF HANNOVER MEDICAL SCHOOL, GERMANY; DR. KEITH JEROME OF THE UNIVERSITY OF WASHINGTON, SEATTLE; DR. HANS-PETER KIEM OF FRED HUTCHINSON CANCER RESEARCH CENTER, SEATTLE; DR. SCOTT KITCHEN OF UCLA; DR. YASUHIRO TAKEUCHI OF UNIVERSITY COLLEGE LONDON; DR. DREW WEISSMAN OF UNIVERSITY OF PENNSYLVANIA IN PHILADELPHIA; AND DR. RICHARD WYATT OF THE SCRIPPS RESEARCH INSTITUTE IN LA JOLLA, CA. IN JUNE 2019, AMFAR AWARDED $1.16 MILLION IN ARCHE GRANTS FOR A PAIR OF INNOVATIVE RESEARCH STUDIES PURSUING DIFFERENT ANGLES TO ATTACK HIV. DR. KEITH JEROME OF THE UNIVERSITY OF WASHINGTON, SEATTLE, WAS AWARDED $344,000 FOR A PROJECT THAT AIMS TO ADVANCE A GENE THERAPY STRATEGY FOR CURING HIV. GENE THERAPY IS VERY PROMISING, BUT IT CARRIES RISKS AND IT IS EXTREMELY EXPENSIVE. AMFARS ARCHE-GT CONSORTIUM PLANS TO REDUCE COSTS BY DEVELOPING IN VIVO GENE THERAPY IN WHICH THE GENE-ENGINEERING TOOLS ARE INJECTED DIRECTLY INTO THE PATIENT USING VECTORS, WHICH FUNCTION AS "TROJAN HORSES". DR. JEROMES TEAM PLANS TO COMPARE WHICH OF 11 VECTORS DELIVERS THE GENE-EDITING TOOLS MOST EFFECTIVELY TO THE VARIOUS SPECIFIC TISSUES THAT ARE BEING TARGETED. THESE LEAD CANDIDATES WILL THEN BE USED IN FUTURE STUDIES OF COMBINATION IN VIVO GENE THERAPY INTERVENTIONS.
AND DR. JONATHAN LI OF BRIGHAM AND WOMEN'S HOSPITAL, BOSTON, WAS	AWARDED $815,000 FOR A PROJECT STUDYING POST-TREATMENT CONTROL OF THE VIRUS (SEE IMPACT GRANTS ABOVE). DR. LI AND HIS TEAM HAVE ASSEMBLED AN IMPRESSIVE COHORT OF POST-TREATMENT CONTROLLERS-INDIVIDUALS WHO EXHIBIT THE RARE ABILITY TO CONTROL THE VIRUS AFTER STOPPING ART-FROM ONE OF THE LARGEST HIV CLINICAL TRIAL NETWORKS GLOBALLY. THE RESEARCH TEAM IS GATHERING AND ANALYZING SAMPLES FROM THIS MULTINATIONAL POST-TREATMENT CONTROL COHORT AND WILL BE ABLE TO EMPLOY CUTTING-EDGE TOOLS TO INVESTIGATE WHETHER CHARACTERISTICS OF THE VIRUS OR IMMUNOLOGIC RESPONSES CAN PREDICT POST-TREATMENT CONTROL. DISCOVERING WHAT LEADS TO POST-TREATMENT CONTROL IN SOME PEOPLE COULD HELP TO ACHIEVE DURABLE ART-FREE CONTROL IN ALL PEOPLE LIVING WITH HIV. MATHILDE KRIM FELLOWSHIPS IN SEPTEMBER 2018, AMFAR ANNOUNCED THE RECIPIENT OF THE 2018 MATHILDE KRIM FELLOWSHIP IN BASIC BIOMEDICAL RESEARCH: DR. YEN-TING LAI OF THE VACCINE RESEARCH CENTER/NATIONAL INSTITUTES OF HEALTH IN BETHESDA, MD. THE 2019 KRIM FELLOWS, DR. MAOLIN LU OF YALE UNIVERSITY IN NEW HAVEN, CT, AND DR. SHAHEED ABDULHAQQ, OF OREGON HEALTH AND SCIENCE UNIVERSITY IN PORTLAND, OR, WERE ANNOUNCED IN SEPTEMBER 2019. THE KRIM FELLOWSHIPS SUPPORT BRIGHT YOUNG SCIENTISTS ADVANCING INNOVATIVE SOLUTIONS TO HIV/AIDS. EACH FELLOW IS AWARDED APPROXIMATELY $150,000 OVER TWO YEARS. PROGRAM SERVICE ACCOMPLISHMENTS (1) CONT. PUBLISHED RESEARCH RESEARCH STUDIES MAKE THE GREATEST IMPACT ON THE HIV FIELD AND ON THE BROADER SCIENTIFIC COMMUNITY WHEN THEY ARE PUBLISHED IN SCIENTIFIC JOURNALS. IN FY2019, 53 SCIENTIFIC PUBLICATIONS RESULTED FROM AMFAR-FUNDED RESEARCH. EXAMPLES INCLUDE: THE "LONDON PATIENT" IS POTENTIALLY CURED FOLLOWING A STEM CELL TRANSPLANT THE "BERLIN PATIENT"-TIMOTHY BROWN-WAS THE FIRST PERSON KNOWN TO HAVE BEEN CURED OF HIV. DIAGNOSED WITH LEUKEMIA, HE RECEIVED A STEM CELL TRANSPLANT FROM A DONOR WITH A RARE GENETIC MUTATION CONFERRING RESISTANCE TO HIV INFECTION. AMFAR'S ICISTEM CONSORTIUM WAS ESTABLISHED TO REPLICATE AND IDENTIFY THE MECHANISMS UNDERLYING HIS CURE, AND HAS ASSEMBLED THE LARGEST COHORT OF PATIENTS WITH HIV WHO HAVE RECEIVED, OR WILL SOON RECEIVE, STEM CELL TRANSPLANTS. IN THE MARCH 2019 ISSUE OF NATURE, DR. RAVI GUPTA AND COLLEAGUES REPORTED ON THE "LONDON PATIENT," THE SECOND INDIVIDUAL POTENTIALLY CURED FOLLOWING A STEM CELL TRANSPLANT. THIS CASE-ALONG WITH THE "DSSELDORF PATIENT," A THIRD POTENTIALLY CURED INDIVIDUAL-IS PROVIDING CRITICAL NEW DATA TO COMPARE WITH THE "BERLIN PATIENT." THE ABILITY TO CONTROL HIV WITHOUT ANTIRETROVIRAL THERAPY RUNS IN FAMILIES CCR5, THE PRIMARY RECEPTOR ENABLING HIV TO INFECT CELLS, IS KNOWN FOR ITS ROLE IN THE CURE OF THE "BERLIN PATIENT" FOLLOWING A STEM CELL TRANSPLANT WITH DONOR CELLS BEARING A MUTATED CCR5 PROTEIN. IN THE APRIL 2019 ISSUE OF ELIFE, DR. STEVEN DEEKS AND COLLEAGUES FOUND ANOTHER WAY THAT CCR5 IS CONNECTED TO THE ABILITY TO CONTROL HIV WITHOUT ART. THE RESEARCHERS STUDIED 131 INDIVIDUALS-ABOUT HALF ELITE AND HALF VIREMIC CONTROLLERS, ABLE TO NATURALLY MAINTAIN VIRAL LOADS OF LESS THAN 50 OR 2000 COPIES, RESPECTIVELY-SOME OF WHOM HAVE BEEN INFECTED SINCE 1980. THEY DISCOVERED THAT CONTROL WAS RELATED TO A NATURAL AND PARTIAL RESISTANCE TO INFECTION IN CONTROLLERS AND NONCONTROLLERS. FURTHER ANALYSIS SHOWED THAT CONTROLLERS HAD LESS CCR5 PRESENT ON THEIR CELLS THAN NONCONTROLLERS, AND THEIR CELLS WERE LESS PERMISSIVE TO HIV INFECTION. FURTHERMORE, NATURAL RESISTANCE TO HIV WAS SHOWN TO BE INHERITED, AS MULTIPLE GENERATIONS OF FAMILY MEMBERS, MALE AND FEMALE, FROM ONE OF THE VIREMIC CONTROLLERS HAD A SIMILAR PROFILE OF LOWERED CCR5. STUDYING HOW AND UNDER WHAT CIRCUMSTANCES THESE CONTROLLERS MAKE LOWER LEVELS OF CCR5 MAY LEAD TO NEW DISCOVERIES THAT COULD INFORM INTERVENTIONS FOR A FUNCTIONAL CURE. IDENTIFYING A BIOMARKER FOR THE 'ACTIVE' HIV RESERVOIR IN THE MAY 2019 ISSUE OF PATHOGENS AND IMMUNITY, DRS. TIMOTHY HENRICH AND PETER HUNT, BOTH AT THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, REPORTED ON EFFORTS TO SEE WHETHER THE PROTEIN CD32-PREVIOUSLY SHOWN TO BE A BIOMARKER FOR HIV ACTIVITY IN BLOOD CELLS-MIGHT ALSO DENOTE ACTIVITY IN THE TISSUES. THE RESEARCHERS EXAMINED GUT BIOPSIES FROM FOUR STUDY PARTICIPANTS WHOSE MEDICATION HAD REDUCED THE HIV IN THEIR BLOOD TO UNDETECTABLE LEVELS. THEY NOTED THAT ABOUT FOUR IN EVERY 100,000 CELLS IN THE TISSUE HAD STARTED ACTIVITY OF THE PROVIRUS, MEANING THEY HAD BEGUN THE FIRST STEPS TOWARDS PRODUCING NEW VIRUSES. THE STUDY CONFIRMED THAT CD32 MAY NOT BE A BIOMARKER OF THE LATENT RESERVOIR, BUT MAY BE A BIOMARKER OF WHAT MIGHT BE CALLED THE "ACTIVE RESERVOIR"-PERSISTENT VIRUS THAT IS PROBABLY FIRST TO RE-SEED INFECTION WHEN ART IS STOPPED. THINKING ON THE NATURE OF THE RESERVOIR IS EVOLVING TO INCLUDE NOT ONLY LATENT, BUT ALSO ACTIVE RESERVOIR, AND BOTH ARE MAJOR BARRIERS TO A CURE. FINDING A WAY TO DIFFERENTIATE CELLS HARBORING ACTIVE RESERVOIR FROM HEALTHY, UNINFECTED CELLS WOULD BE AN IMPORTANT ADVANCE. HIV CURE SUMMIT IN DECEMBER 2018, AMFAR HELD ITS FIFTH ANNUAL HIV CURE SUMMIT AT THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (UCSF), WHERE THE AMFAR INSTITUTE FOR HIV CURE RESEARCH IS BASED. LEADING AMFAR-FUNDED CURE RESEARCHERS DETAILED THEIR PROGRESS AND DISCUSSED THE SCIENTIFIC CHALLENGES THAT CONTINUE TO STAND IN THE WAY OF A CURE. MUCH OF THE DISCUSSION CENTERED ON ANALYTIC TREATMENT INTERRUPTION. THE ONLY MEANS CURRENTLY AVAILABLE FOR PROVING THAT A PERSON HAS BEEN CURED IS TO REMOVE ANTIRETROVIRAL THERAPY UNDER CLOSELY CONTROLLED AND MONITORED CONDITIONS. DR. ROWENA JOHNSTON, AMFAR VICE PRESIDENT AND DIRECTOR OF RESEARCH, ELUCIDATED THE TWO TYPES OF CURE THAT RESEARCHERS ARE PURSUING: ERADICATION AND POST-TREATMENT CONTROL. IN ERADICATION, AN INDIVIDUAL COMPLETELY CLEARS HIV FROM HIS OR HER BODY; AND IN POST-TREATMENT CONTROL SOME VIRUS REMAINS, BUT THE IMMUNE SYSTEM CAN CONTROL IT WITHOUT ART. DR. STEVEN DEEKS, A PROFESSOR OF MEDICINE AT UCSF AND A LEAD INVESTIGATOR AT THE AMFAR INSTITUTE, EXPLAINED THE COMPLEX CLINICAL STUDY HE IS ABOUT TO EMBARK ON. IN THE STUDY, DR. DEEKS AND HIS TEAM WILL ADMINISTER A SERIES OF THERAPEUTIC VACCINES, BROADLY NEUTRALIZING ANTIBODIES, AND AN AGENT TO SHOCK THE VIRUS OUT OF ITS HIDING PLACES. THE SUMMIT ALSO FEATURED A RANGE OF PERSPECTIVES FROM MEMBERS OF THE COMMUNITY ADVISORY BOARD FOR THE AMFAR INSTITUTE AND OTHER COMMUNITY LEADERS. THINK TANKS CONSISTENT WITH AMFARS COMMITMENT TO INVESTIGATE EVERY AVENUE THAT MAY LEAD TO A CURE, THE FOUNDATION REGULARLY HOSTS THINK TANKS THAT BRING TOGETHER LEADING INVESTIGATORS IN VARIOUS FIELDS. IN MARCH 2019, AMFAR HOSTED A THINK TANK ON GENE THERAPY. EXPERTS GATHERED TO DISCUSS CUTTING-EDGE APPROACHES TO CURING HIV THAT AMFAR COULD PURSUE THROUGH ITS GENE THERAPY RESEARCH INITIATIVE, ARCHE-GT. IN MAY 2019, MEMBERS OF AMFARS ICISTEM CONSORTIUM OF EUROPEAN RESEARCHERS THAT AIMS TO REPLICATE THE CASE OF "THE BERLIN PATIENT" GATHERED FOR A THINK TANK IN DUBLIN, IRELAND. ICISTEM WAS CREATED AND IS FUNDED BY AMFAR THROUGH ITS COUNTDOWN TO A CURE FOR AIDS INITIATIVE. AND IN AUGUST 2019, AMFAR HOSTED A THINK TANK IN NEW YORK CITY ON THE CCR5 RECEPTOR AS A TARGET IN CURE RESEARCH. THE RESEARCHERS DISCUSSED WAYS TO USE CCR5 TO DEVELOP A MORE GENERALIZABLE CURE THAN ONE INVOLVING RISKY AND COSTLY STEM CELL TRANSPLANTS.
PROGRAM SERVICE ACCOMPLISHMENTS (2)	LINE 4B: TREAT ASIA: AMFARS TREAT ASIA (THERAPEUTICS RESEARCH, EDUCATION, AND AIDS TRAINING IN ASIA) PROGRAM IS A NETWORK OF HOSPITALS, CLINICS, AND RESEARCH INSTITUTIONS WORKING WITH CIVIL SOCIETY TO ENSURE THE SAFE AND EFFECTIVE DELIVERY OF TREATMENTS FOR HIV AND ITS CO-INFECTIONS TO ADULTS AND CHILDREN ACROSS THE ASIA-PACIFIC THROUGH RESEARCH, EDUCATION, AND ADVOCACY OF EVIDENCE-BASED HIV-RELATED POLICIES. THE TREAT ASIA NETWORK ENCOMPASSES 21 ADULT AND 20 PEDIATRIC SITES THROUGHOUT THE REGION, WHICH COLLABORATE ON A VARIETY OF PROJECTS. TREAT ASIA SCIENTISTS PRODUCED 38 PUBLICATIONS IN PEER-REVIEWED MEDICAL JOURNALS IN 2019. INTERNATIONAL AIDS DATABASE TREAT ASIA MANAGES THE ASIA-PACIFIC SECTION OF THE INTERNATIONAL EPIDEMIOLOGY DATABASES TO EVALUATE AIDS (IEDEA), A GLOBAL COLLABORATION ESTABLISHED BY THE U.S. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES. IN FY2019, THE IEDEA CONSORTIUM COMPLETED STAY (STUDY OF TRANSITIONING ASIAN YOUTH), WHICH AIMS TO DOCUMENT THE EXPERIENCE OF HIV-POSITIVE YOUNG ADULTS WHO ARE TRANSITIONING FROM PEDIATRIC TO ADULT CARE. TREAT ASIA HIV OBSERVATIONAL DATABASE (TAHOD) TREAT ASIA PIONEERED THE REGIONS FIRST ADULT OBSERVATIONAL DATABASE FOR HIV/AIDS, WHICH NOW INCLUDES ANONYMOUS DATA FROM NEARLY 10,000 PATIENTS AT 21 CLINICAL SITES IN 12 COUNTRIES. THE INFORMATION GATHERED IN THE DATABASE INFORMS THE DEVELOPMENT OF MORE EFFECTIVE RESEARCH AND TREATMENT PROGRAMS AND HELPS DEFINE TREATMENT STANDARDS SPECIFIC TO HIV/AIDS IN ASIA. TAHOD LOW-INTENSITY TRANSFER LAUNCHED IN 2014, TAHOD LOW-INTENSITY TRANSFER (TAHOD-LITE) CONTAINS DATA FROM OVER 37,000 HIV-POSITIVE PATIENTS ACROSS TEN TREAT ASIA NETWORK SITES. AS AN EXTENSION OF TAHOD, TAHOD-LITE AIMS TO INCREASE THE SCOPE OF ADULT DATA COLLECTION BY GATHERING A SUBSET OF CORE VARIABLES FROM THE ENTIRE COHORT OF HIV-INFECTED PATIENTS WHO HAVE SOUGHT CARE AT SELECTED TAHOD SITES. TREAT ASIA PEDIATRIC HIV OBSERVATIONAL DATABASE THE TREAT ASIA PEDIATRIC HIV OBSERVATIONAL DATABASE (TAPHOD) IS A REGIONAL PEDIATRIC HIV STUDY SET UP BY TREAT ASIA IN 2006. IT WAS MODELED AFTER THE ADULT DATABASE AND INCLUDES DATA FROM MORE THAN 6,400 CHILDREN AND ADOLESCENTS AT 17 CLINICAL SITES IN CAMBODIA, INDIA, INDONESIA, MALAYSIA, THAILAND, AND VIETNAM. INTEGRATING HIV, MENTAL HEALTH, AND IMPLEMENTATION SCIENCE RESEARCH IN MAY 2019, THE U.S. NATIONAL INSTITUTES OF HEALTH AWARDED A FIVE-YEAR, $1.4 MILLION GRANT TO TREAT ASIA AND COLUMBIA UNIVERSITY TO ESTABLISH AN INNOVATIVE PLATFORM FOR INTEGRATING HIV, MENTAL HEALTH, AND IMPLEMENTATION SCIENCE RESEARCH IN THE ASIA-PACIFIC REGION. THE OBJECTIVE OF THE CHIMERA PROGRAM (CAPACITY DEVELOPMENT FOR HIV AND MENTAL HEALTH RESEARCH IN ASIA) IS TO ADDRESS THE DUAL AND INTERLINKED BURDENS OF HIV AND MENTAL HEALTH. CO-LED BY PRINCIPAL INVESTIGATORS DR. ANNETTE SOHN, AMFAR VICE PRESIDENT AND DIRECTOR OF TREAT ASIA, AND DR. MILTON WAINBERG, PROFESSOR OF CLINICAL PSYCHIATRY AT COLUMBIA UNIVERSITY AND THE NEW YORK STATE PSYCHIATRIC INSTITUTE, THE PROGRAM AIMS TO BUILD A TEAM WITHIN THE ASIA-PACIFIC WITH THE CAPACITY TO LEAD REGIONAL HIV-MENTAL HEALTH-IMPLEMENTATION SCIENCE RESEARCH THAT WILL INFORM PUBLIC HEALTH POLICY AND IMPROVE THE QUALITY OF CLINICAL CARE FOR PEOPLE LIVING WITH HIV. THE PROGRAM IS NESTED WITHIN THE IEDEA (SEE ABOVE) ASIA-PACIFIC REGIONAL RESEARCH NETWORK THAT TREAT ASIA DIRECTS. CHIMERA WILL CREATE THE OPPORTUNITY TO BRING TOGETHER STELLAR TRAINING FACULTY FROM ACADEMIC CENTERS AND PUBLIC HEALTH AND DEVELOPMENT AGENCIES WITHIN THE REGION AND ACROSS THE WORLD, AND WILL BUILD ON EXISTING NIH-FUNDED MENTAL HEALTH RESEARCH BEING CONDUCTED THROUGH IEDEA ASIA-PACIFIC. EMPOWERING YOUTH ADVOCATES IN DECEMBER 2018, TREAT ASIAS YOUTH ACATA-ASIA COMMUNITY FOR AIDS TREATMENT AND ADVOCACY-HELD A WORKSHOP IN BANGKOK. FOCUSED ON MODELS OF SERVICE DELIVERY FOR KEY POPULATIONS, THE WORKSHOP INCLUDED SITE VISITS TO COMMUNITY-BASED OR KEY POPULATION-FRIENDLY HIV SERVICE PROVIDERS IN BANGKOK. EXPANDING ACCESS TO HIV TREATMENT IN 2018, THE WORLD HEALTH ORGANIZATION (WHO) RECOMMENDED DOLUTEGRAVIR (DTG)-BASED REGIMENS AS THE PREFERRED FIRST-LINE HIV TREATMENT FOR ADULTS AND ADOLESCENTS. BUT IN THE ASIA-PACIFIC REGION, ACCESS TO DTG-BASED REGIMENS REMAINS SEVERELY LIMITED. TO ACCELERATE DTG SCALE-UP IN THE REGION, TREAT ASIA AND THE CLINTON HEALTH ACCESS INITIATIVE ORGANIZED A WORKSHOP IN BANGKOK IN MARCH 2019 TO HELP NETWORKS OF PEOPLE LIVING WITH HIV AND OTHER TREATMENT ACCESS ADVOCATES BETTER UNDERSTAND ISSUES AROUND DTG ACCESS AND USE, AND COORDINATE FUTURE ADVOCACY EFFORTS. ATTENDED BY 25 PARTICIPANTS FROM NINE ASIAN COUNTRIES, THE WORKSHOP BUILT UPON EARLIER COLLABORATIVE EFFORTS WITH THE WHO SOUTH EAST ASIA AND WESTERN PACIFIC REGIONAL OFFICES TO ENHANCE ACCESS TO NEWER HIV AND HEPATITIS C MEDICATIONS. IN APRIL 2019, GITEN KHWAIRAKPAM, TREAT ASIAS PROJECT MANAGER FOR COMMUNITY AND POLICY, LED A TRAINING IN BANGKOK FOR REGIONAL COMMUNITY ADVOCATES AROUND THE USE OF DTG. AND THE FOLLOWING MONTH, TREAT ASIA CO-ORGANIZED A WEBINAR WITH THE WHO WESTERN PACIFIC OFFICE AROUND THE USE OF DTG AND ACCESS ISSUES IN THE REGION. HELPING ADOLESCENTS TRANSITION TO ADULT CARE THERE ARE INCREASINGLY LARGE NUMBERS OF YOUNG ADULTS IN THE ASIA-PACIFIC REGION WITH RECENTLY ACQUIRED INFECTIONS. IN 2017, 30% OF NEW HIV INFECTIONS IN THE ASIA-PACIFIC OCCURRED IN PEOPLE AGED 15-24 YEARS. CONTINUING ITS COMMITMENT TO HELPING ADOLESCENTS TRANSITION TO ADULT CARE, IN JANUARY 2019 TREAT ASIA HELD A THINK TANK ON YOUNG ADULT COHORT RESEARCH TO EXPLORE OPPORTUNITIES FOR A NEW COHORT STUDY FOCUSING ON YOUNG ADULTS. ADVOCATING FOR CO-INFECTION TREATMENT ACCESS IN JUNE 2019, TREAT ASIA HELD ITS ANNUAL REGIONAL ADVOCACY MEETING ON HEPATITIS C, HIV, AND TUBERCULOSIS TREATMENT IN BANGKOK, WITH CIVIL SOCIETY ORGANIZATIONS, CLINICAL CARE PROFESSIONALS, AND INTELLECTUAL PROPERTY EXPERTS. DURING THE YEAR, TREAT ASIA ALSO ATTENDED AND PRESENTED AT SEVERAL CONFERENCES ON HEPATITIS C TREATMENT ACCESS AND PARTNERED WITH CIVIL SOCIETY GROUPS AND FUNDERS ON ADVOCACY EFFORTS. PUBLICATIONS TREAT ASIA DIRECTOR DR. ANNETTE SOHN CO-AUTHORED AN OP-ED FOR ASIA-PACIFIC BIOTECH NEWS, TITLED "ASIA-PACIFIC: FALLING BEHIND IN THE FIGHT AGAINST HIV/AIDS." THE OP-ED, COAUTHORED BY A SINGAPOREAN INVESTIGATOR, DISCUSSED THE CURRENT STATE OF THE HIV EPIDEMIC IN ASIA, AND HIGHLIGHTED PRIORITY ISSUES FOR THE REGIONAL RESPONSE. IN JANUARY 2019, TREAT ASIA PRODUCED THE FACT SHEET, WHO GUIDELINES FOR THE SCREENING, CARE, AND TREATMENT OF PERSONS WITH HEPATITIS C INFECTION. THE FACT SHEET SUMMARIZES WHO GUIDELINES (UPDATED, JULY 2018) ON CARE AND TREATMENT OF HEPATITIS C VIRUS INFECTION, WHICH ARE AIMED AT HELPING POLICYMAKERS AND HEALTHCARE PROVIDERS IN LOW- AND MIDDLE-INCOME COUNTRIES ESTABLISH SCREENING, CARE, AND TREATMENT PROGRAMS. AND IN FEBRUARY 2019, TREAT ASIA UPDATED THE BROCHURE, TREAT ASIA: A COOPERATIVE APPROACH TO COMBATING HIV IN ASIA AND THE PACIFIC, WHICH HIGHLIGHTS KEY FACTS AND FIGURES OF THE HIV EPIDEMIC IN THE REGION. THE BROCHURE MAKES THE CASE THAT TREAT ASIAS UNIQUE CAPACITY TO BRING TOGETHER RESEARCHERS, CLINICIANS, ADVOCATES, AND POLICYMAKERS PLAYS AN IMPORTANT ROLE IN THE REGIONS RESPONSE TO HIV/AIDS, AND HAS BECOME A MODEL FOR REGIONAL COLLABORATION. IN ADDITION, TREAT ASIA CONTINUED TO PUBLISH LAY-LANGUAGE ARTICLES ON HIV/AIDS RESEARCH, POLICY, AND COMMUNITY ISSUES FACING THE ASIA-PACIFIC AS A WHOLE. THE ARTICLES AND EDUCATIONAL PIECES APPEAR IN THE TREAT ASIA REPORT, A BIMONTHLY E-NEWSLETTER, AND ON TREAT ASIAS WEBSITE, WWW.TREATASIA.ORG. 18TH ANNUAL NETWORK MEETING THE 2018 TREAT ASIA ANNUAL NETWORK MEETING WAS HELD IN OCTOBER 2018 IN BANGKOK, THAILAND, WHERE MORE THAN 120 ADULT AND PEDIATRIC INVESTIGATORS, DONORS, AND PROGRAM PARTNERS GATHERED TO REVIEW PROGRESS ON THE NETWORKS RESEARCH AGENDA, HEAR ABOUT REGIONAL HIV-RELATED POLICY PRIORITIES, AND PLAN FOR FUTURE INITIATIVES. OTHER CONFERENCES TREAT ASIA STAFF AND NETWORK INVESTIGATORS ATTENDED AND PRESENTED AT SEVERAL REGIONAL AND INTERNATIONAL CONFERENCES ON HIV-RELATED ISSUES. EXAMPLES INCLUDE: IAS 2019 TREAT ASIA HAD A STRONG PRESENCE AT THE 10TH INTERNATIONAL AIDS SOCIETY CONFERENCE ON HIV SCIENCE (IAS 2019) IN MEXICO CITY IN JULY. TREAT ASIA DIRECTOR DR. ANNETTE SOHN CO-CHAIRED A SPECIAL SESSION WITH FORMER IAS PRESIDENT DR. CHRIS BEYRER OF JOHNS HOPKINS UNIVERSITY, CALLED "DATA LEADING THE WAY: DESIGNING RESPONSES BASED ON THE NUMBERS." DR. SOHN WAS ALSO A SESSION CO-CHAIR AT THE INTERNATIONAL WORKSHOP ON HIV PEDIATRICS, WHICH CONVENED IMMEDIATELY BEFORE IAS 2019. GITEN KHWAIRAKPAM, TREAT ASIA'S PROJECT MANAGER FOR COMMUNITY AND POLICY, CO-CHAIRED THE 5TH INTERNATIONAL HIV/VIRAL HEPATITIS CO-INFECTION PRECONFERENCE.
PROGRAM SERVICE ACCOMPLISHMENTS (2) CONT.	APACC TREAT ASIA WAS ALSO WELL REPRESENTED AT THE FOURTH ASIA PACIFIC AIDS & CO-INFECTIONS CONFERENCE (APACC), HELD IN JUNE 2019 IN HONG KONG. SEVERAL JUNIOR INVESTIGATORS AND PH.D. STUDENTS AFFILIATED WITH THE TREAT ASIA NETWORK GAVE ORAL AND POSTER PRESENTATIONS AT THE CONFERENCE. APACC IS A REGIONAL-LEVEL HIV RESEARCH CONFERENCE THAT PROVIDES OPPORTUNITIES FOR LOCAL CLINICIANS, STUDENTS, AND RESEARCHERS TO SUBMIT ABSTRACTS FOR PRESENTATION.
PROGRAM SERVICE ACCOMPLISHMENTS (3)	LINE 4C: PUBLIC INFORMATION: AMFAR SEEKS TO TRANSLATE AND DISSEMINATE INFORMATION ON IMPORTANT HIV-RELATED RESEARCH, TREATMENT, PREVENTION, AND POLICY ISSUES FOR DIVERSE AUDIENCES AND TO INCREASE AWARENESS AND KNOWLEDGE OF THE PANDEMIC. AMFAR PUBLISHES A WIDE RANGE OF EDUCATIONAL MATERIALS, MAINTAINS AN INFORMATIVE WEBSITE, AND ENGAGES RESPECTED PUBLIC FIGURES, HIV/AIDS SCIENTISTS, AND POLICYMAKERS IN COMMUNICATING THE NEED FOR CONTINUED RESEARCH TO DEVELOP NEW METHODS OF PREVENTION, TREATMENT, AND, ULTIMATELY, A CURE FOR HIV. EDUCATIONAL MATERIALS AMFAR PRODUCES A RANGE OF PERIODICALS IN BOTH PRINT AND ELECTRONIC FORMATS, INCLUDING ITS NEWSLETTER INNOVATIONS, PUBLISHED TWICE A YEAR AND DISTRIBUTED TO MORE THAN 40,000 PEOPLE; THE TREAT ASIA REPORT, AN EMAIL NEWSLETTER DISTRIBUTED SIX TIMES A YEAR TO MORE THAN 4,000 READERS IN THE INTERNATIONAL HEALTH COMMUNITY; AND A MONTHLY E-MAIL NEWSLETTER DISTRIBUTED TO APPROXIMATELY 11,000 PEOPLE. IN 2019, AMFAR REMOVED OUTDATED ADDRESSES FROM ITS EMAIL LIST AND SIGNIFICANTLY IMPROVED ENGAGEMENT WITH ITS AUDIENCE. THE MONTHLY OPEN RATE INCREASED FROM AN AVERAGE OF ABOUT 10% TO 30%. THE FOUNDATIONS WEBSITES-WWW.AMFAR.ORG AND WWW.CURECOUNTDOWN.ORG-FEATURE NEWS, INTERVIEWS, AND ORIGINAL ARTICLES COVERING HIV RESEARCH, POLICY, THE GLOBAL EPIDEMIC, AND AMFAR PROGRAMS AND ACTIVITIES. THE WEBSITES ATTRACT A COMBINED AVERAGE OF 36,000 VISITORS PER MONTH. AMFAR ALSO CREATES AND DISTRIBUTES REPORTS, PRESS RELEASES, AND UPDATES ON MAJOR HIV/AIDS ISSUES AND CONDUCTS PUBLIC SERVICE ADVERTISING CAMPAIGNS THAT HAVE BEEN INSTRUMENTAL IN EDUCATING POLICYMAKERS, HEALTHCARE PROFESSIONALS, PEOPLE LIVING WITH HIV/AIDS, AND THE PUBLIC. PUBLIC POLICY AMFARS PUBLIC INFORMATION TEAM WORKS CLOSELY WITH THE PUBLIC POLICY OFFICE (SEE ABOVE) TO PRODUCE A WIDE RANGE OF ISSUE BRIEFS, FACTS SHEETS, INFOGRAPHICS, AND REPORTS. IN 2019 IT ALSO WORKED WITH AN ANIMATION STUDIO TO PRODUCE A SHORT FILM SHOWCASING THE FEATURES AND FUNCTIONALITY OF AMFARS OPIOID & HEALTH INDICATORS DATABASE (OPIOID.AMFAR.ORG). EPIC VOICES AMFARS EPIC VOICES, AN ONLINE VIDEO SERIES THAT AIMS TO REENERGIZE THE RESPONSE TO HIV AMONG MILLENNIAL AND LGBTQ COMMUNITIES CONTINUED TO GENERATE SIGNIFICANT PUBLICITY WITH SEVERAL NEW STORIES PUBLISHED IN 2019. LAUNCHED IN 2017, THE GOALS OF THE CAMPAIGN ARE TO: RENEW AWARENESS OF THE PERSISTENT THREAT OF HIV, UNDERSCORE THE URGENT NEED TO SUPPORT HIV RESEARCH, AND SUPPORT AMFARS LEADERSHIP IN THE SEARCH FOR A CURE. AMFAR SPOKE TO HIV ACTIVISTS ACROSS THE COUNTRY AND ASKED THEM TO SHARE THEIR UNIQUE JOURNEYS, THEIR INSIGHTS ON LIVING WITH HIV, AND THE BOLD STEPS THEY HAVE TAKEN IN THE FIGHT AGAINST THE EPIDEMIC. SOCIAL MEDIA AMFAR HAS VIGOROUSLY EXPANDED ITS PRESENCE IN THE SOCIAL MEDIA ARENA, REACHING LARGE NUMBERS OF PEOPLE, INCLUDING A YOUNGER DEMOGRAPHIC THAT IS OFTEN LESS EDUCATED ABOUT HIV AND THE AIDS EPIDEMIC. THE FOUNDATION REGULARLY ADDS CONTENT TO ITS FACEBOOK PAGE, LIVE TWEETS FROM EVENTS, AND POSTS IMAGES ON INSTAGRAM FROM FUNDRAISING AND PROGRAM EVENTS. AMFAR HAS 73,000 LIKES ON FACEBOOK, MORE THAN 43,000 TWITTER FOLLOWERS, AND 164,000 INSTAGRAM FOLLOWERS. MEDIA OUTREACH IN FY2019, AMFAR CONTINUED TO WORK CLOSELY WITH THE MEDIA TO RAISE THE PROFILE OF HIV/AIDS, BOTH DOMESTICALLY AND INTERNATIONALLY, AND TO HELP ENSURE THE ACCURACY OF HIV-RELATED PRESS COVERAGE. ARTICLES AND REPORTS INVOLVING AMFAR-MANY OF WHICH INCLUDED INTERVIEWS WITH STAFF-WERE CARRIED IN NUMEROUS MEDIA OUTLETS, INCLUDING THE NEW YORK TIMES, WIRED, SCIENCE, THE WASHINGTON POST, BANGKOK POST, USA TODAY, U.S. NEWS & WORLD REPORT, PEOPLE, VOX, VOGUE, VANITY FAIR, ESSENCE, BUSTLE, THE ADVOCATE, POZ, CBS NEWS, NBC NEWS, ABC NEWS, FOX NEWS, NPR, ASSOCIATED PRESS, AND REUTERS. CELEBRITY SUPPORT AMFARS PUBLIC AWARENESS EFFORTS ARE GREATLY ENHANCED BY THE COMMITTED SUPPORT OF PUBLIC FIGURES WHO LEND THEIR VOICES AND DONATE THEIR TIME, TALENTS, AND RESOURCES TO HELP SUSTAIN THE FOUNDATIONS MISSION. SUPPORT OF AMFAR BY PROMINENT PUBLIC FIGURES BEGAN WITH THE LATE DAME ELIZABETH TAYLOR, AMFARS FOUNDING INTERNATIONAL CHAIRMAN, AND OTHERS HAVE FOLLOWED IN HER FOOTSTEPS. AMFAR IS PROFOUNDLY GRATEFUL FOR THE CONTINUING SUPPORT OF CELEBRITIES FROM ALL OVER THE WORLD. CELEBRITY SUPPORTERS INCLUDED KATY PERRY, DAME SHIRLEY BASSEY, DARREN CRISS, JUDD APATOW, ROBERT PATTINSON, MATT BOMER, DIANA ROSS, JAY ELLIS, ZOE SALDANA, GRACE JONES, MILLA JOVOVICH, MERT ALAS AND MARCUS PIGGOTT, KIM KARDASHIAN, KOURTNEY KARDASHIAN, HEIDI KLUM, ALAN CUMMING, MICHELLE RODRIGUEZ, KAROLINA KURKOVA, ALESSANDRA AMBROSIO, CAROLINE VREELAND, CANDICE SWANEPOEL, ELSA HOSK, KAREN ELSON, LAIS RIBEIRO, VICTORIA JUSTICE, WINNIE HARLOW, ALEXANDER SKARSGRD, PHARRELL WILLIAMS, MICHELLE YEOH, KYLE MACLACHLAN, NICOLE SCHERZINGER, LAY ZHANG, MARIAH CAREY, DUA LIPA, TOM JONES, CHARLI XCX, CHRIS TUCKER, CARINE ROITFELD, ANDREAS SCHAGER, HENRY GOLDING, EVA LONGORIA, ANDIE MACDOWELL, NATASHA POLY, PATRICIA ARQUETTE, ANTONIO BANDERAS, ORLANDO BLOOM, IAN BOHEN, ADRIEN BRODY, KENDALL JENNER, H.E.R., TOMMY HILFIGER, KRIS JENNER, JULIAN LENNON, ADRIANA LIMA, COCO ROCHA, SARA SAMPAIO, CHRISTOPH WALTZ, REBEL WILSON, CEELO GREEN, JOAN SMALLS, AND RITA ORA.
PROGRAM SERVICE ACCOMPLISHMENTS (5)	LINE 4D: PUBLIC POLICY: INFORMED BY THOROUGH RESEARCH AND ANALYSIS, AMFAR IS A HIGHLY RESPECTED ADVOCATE OF RATIONAL AND COMPASSIONATE HIV/AIDS-RELATED PUBLIC POLICY. THE FOUNDATION IS ENGAGED IN EFFORTS TO SECURE NECESSARY INCREASES IN FUNDING FOR HIV/AIDS RESEARCH AND GLOBAL HIV/AIDS PROGRAMS, EXPAND ACCESS TO TREATMENT AND CARE FOR MARGINALIZED POPULATIONS, ADVOCATE HARM REDUCTION POLICIES AIMED AT REDUCING THE SPREAD OF HIV AND HEPATITIS C (HCV) AMONG PEOPLE WHO INJECT DRUGS, AND PROTECT THE CIVIL RIGHTS OF ALL PEOPLE AFFECTED BY OR VULNERABLE TO HIV/AIDS. ENDING THE DOMESTIC HIV EPIDEMIC DURING THE 2019 STATE OF THE UNION, PRESIDENT TRUMP ANNOUNCED A PLAN TO END HIV TRANSMISSIONS IN THE U.S. BY 2030. THE ENDING THE HIV EPIDEMIC INITIATIVE (EHE) AIMS TO REDUCE HIV INFECTIONS BY 75% IN FIVE YEARS, AND BY 90% IN TEN YEARS. IN 2019, AMFAR LAUNCHED A FREE INTERACTIVE DATABASE (EHE.AMFAR.ORG) TO HELP POLICYMAKERS, PUBLIC HEALTH OFFICIALS, ADVOCATES, AND OTHER STAKEHOLDERS UNDERSTAND THE OPPORTUNITIES AND CHALLENGES ACROSS EHE JURISDICTIONS. THE EHE DATABASE INCLUDES DEMOGRAPHIC, POLICY, AND SERVICE PROVIDER INFORMATION, AND EPIDEMIOLOGICAL INDICATORS. IN 2018 THE TRUMP ADMINISTRATION PROPOSED A RULE CHANGE TO THE TITLE X NATIONAL FAMILY PLANNING PROGRAM, STATING THAT HEALTH PROVIDERS IN THE TITLE X PROGRAM "MAY NOT PERFORM, PROMOTE, REFER FOR, OR SUPPORT ABORTION." THE STIPULATION IS COMMONLY KNOWN AS THE DOMESTIC GAG RULE. IN FEBRUARY 2019, AMFAR PUBLISHED TITLE X, THE DOMESTIC GAG RULE, AND THE HIV RESPONSE, AN ISSUE BRIEF ILLUSTRATING THE BENEFITS OF THE TITLE X PROGRAM AND POTENTIAL IMPACTS OF THE GAG RULE. ANALYSIS FROM THE REPORT SHOWS THAT, IF IMPLEMENTED, THE DOMESTIC GAG RULE COULD NOT ONLY UNDERMINE WOMENS ACCESS TO REPRODUCTIVE HEALTH SERVICES, BUT ALSO IMPEDE ACCESS TO HIV TESTING FOR LOW-INCOME POPULATIONS, THREATENING THE NATIONAL RESPONSE TO THE HIV EPIDEMIC. AND IN MARCH 2019, AMFAR PUBLISHED AN ISSUE BRIEF TITLED EXPANDING ACCESS TO PRE-EXPOSURE PROPHYLAXIS (PREP) FOR ADOLESCENTS AND YOUNG ADULTS: MODELS FOR ADDRESSING CONSENT, CONFIDENTIALITY, AND PAYMENT BARRIERS. ENSURING THAT ADOLESCENTS AND YOUNG ADULTS AT RISK FOR HIV CAN ACCESS PREP IS A KEY STEP TOWARD REDUCING THE NUMBER OF HIV DIAGNOSES. HIV AND THE OPIOID EPIDEMIC AMFAR MAINTAINS AN IMPORTANT AND WIDELY USED RESOURCE ON HIV AND THE OPIOID EPIDEMIC. ITS OPIOID & HEATH INDICATORS DATABASE (OPIOID.AMFAR.ORG) IS A FREE WEB PLATFORM DESIGNED TO SUPPORT LAWMAKERS, COMMUNITIES AND ADVOCATES IN MAKING INFORMED DECISIONS ABOUT THE OPIOID EPIDEMIC AND ITS IMPACT ON HIV AND HEPATITIS C. THE SITE IS A WINDOW INTO THE OPIOID EPIDEMIC UNFOLDING IN EVERY AMERICANS BACKYARD. IT PROVIDES LOCAL TO NATIONAL STATISTICS USING RELIABLE DATA SOURCES ON NEW HIV AND HEPATITIS C INFECTIONS, OPIOID USE AND OVERDOSE DEATH RATES, AND THE AVAILABILITY OF SERVICES LIKE DRUG TREATMENT PROGRAMS AND SYRINGE EXCHANGE SERVICES. IN OCTOBER 2018, AMFAR PUBLISHED AN ANALYSIS IN HEALTH AFFAIRS ON THE LOW PERCENTAGE OF SUBSTANCE USE FACILITIES THAT TEST FOR HIV OR HEPATITIS C. THE NEW YORK TIMES PUBLISHED SEVERAL ARTICLES HIGHLIGHTING THE BIPARTISAN OPIOID BILL PASSED BY CONGRESS THAT LINKED TO AMFARS ORIGINAL HEALTH AFFAIRS ANALYSIS ON THE DEARTH OF SUBSTANCE USE TREATMENT FACILITIES THAT OFFER MEDICATION-ASSISTED TREATMENT (MAT) NATIONWIDE. THE NUMBER OF DRUG-RELATED POISONING DEATHS IN THE UNITED STATES MORE THAN TRIPLED BETWEEN 1999 AND 2017, ACCOMPANIED BY A RISE IN INJECTION DRUG USE. SINCE UPTAKE OF TREATMENT FOR SUBSTANCE USE DISORDER AND HARM REDUCTION SERVICES AT SYRINGE SERVICES PROGRAMS (SSPS) CAN REDUCE THE RISK OF HIV AND HEPATITIS C ACQUISITION, ACCESS TO SERVICES IS CRITICALLY IMPORTANT. IN NOVEMBER 2018, AMFAR PUBLISHED GETTING TO SERVICES: FAR, FAR AWAY, AN INFOGRAPHIC SHOWING HOW FAR AMERICANS MUST TRAVEL TO SUBSTANCE USE CLINICS OFFERING MAT AND SSPS. NEARLY 30% OF AMERICANS LIVE MORE THAN TEN MILES FROM A FACILITY PROVIDING MEDICATION-ASSISTED TREATMENT, AND NEARLY 80% LIVE MORE THAN TEN MILES FROM AN SSP. ACCORDING TO ONE STUDY, PEOPLE TYPICALLY DO NOT ACCESS SSPS IF THEY ARE MORE THAN TEN MILES FROM WHERE THEY LIVE. IN AUGUST 2019, AMFAR SENIOR POLICY AND MEDICAL ADVISOR DR. SUSAN BLUMENTHAL PENNED AN OP-ED ON THRIVEGLOBAL ON THE NEED FOR A STRATEGIC PLAN FOR ADDRESSING THE OPIOID EPIDEMIC PARALLELING WHAT WAS DONE FOR HIV. GLOBAL HEALTH IN OCTOBER 2018, AMFAR PUBLISHED A FIRST-OF-ITS-KIND ANALYSIS THAT ATTEMPTED TO QUANTIFY INDIRECT COSTS CHARGED BY ORGANIZATIONS IMPLEMENTING THE U.S. PRESIDENTS EMERGENCY PLAN FOR AIDS RELIEF (PEPFAR). EXAMINING DATA FROM 2007 TO 2016, THE STUDY FOUND THAT BETWEEN $1.85 BILLION AND $4.34 BILLION WAS SPENT ON INDIRECT COSTS. THE STUDY WAS PUBLISHED IN THE PEER-REVIEWED ONLINE JOURNAL PLOS ONE, AND CALLED FOR INCREASED TRANSPARENCY IN REPORTING INDIRECT COSTS INCURRED BY PEPFAR. AT THE BIENNIAL HIV RESEARCH FOR PREVENTION CONFERENCE IN MADRID IN OCTOBER 2018, AMFAR POLICY ASSOCIATE JENNIFER SHERWOOD AND COLLEAGUES PRESENTED FINDINGS FROM A SURVEY USED TO TRACK THE IMPACT OF THE EXPANDED MEXICO CITY POLICY ON THE OPERATIONS AND SERVICE DELIVERY OF ORGANIZATIONS RECEIVING ASSISTANCE THROUGH PEPFAR. THE MEXICO CITY POLICY, OR "GLOBAL GAG RULE," WAS REINSTATED AND EXPANDED BY PRESIDENT TRUMP IN 2017. IT NOW RESTRICTS NON-U.S.-BASED OR FOREIGN NGOS FROM RECEIVING AMERICAN FINANCIAL AID IF THEY PERFORM, COUNSEL ON, OR REFER FOR ABORTION, OR ADVOCATE FOR ITS LIBERALIZATION OUTSIDE OF LIMITED EXCEPTIONS. IN JANUARY 2019, AMFAR PUBLISHED AN ISSUE BRIEF REPORTING ON DISRUPTIONS IN SERVICE PROVISION DUE TO THE EXPANDED MEXICO CITY POLICY. BASED ON THE SURVEY DESCRIBED ABOVE, AMFAR REVEALED THAT PEPFAR PARTNERS IN 31 COUNTRIES REPORTED DISRUPTIONS IN SERVICE PROVISION DUE TO THE POLICY. THESE FINDINGS HAVE SERIOUS IMPLICATIONS FOR REPRODUCTIVE HEALTH AND THE GLOBAL HIV EPIDEMIC. IN FEBRUARY 2019, AMFAR PUBLISHED A COMPANION INFOGRAPHIC, PEPFAR PROGRAMMING DISRUPTED BY EXPANDED MEXICO CITY POLICY. IN DECEMBER 2018, AMFAR LAUNCHED THE PEPFAR MONITORING, EVALUATION, AND REPORTING (MER) DATABASE (MER.AMFAR.ORG). THE MER DATABASE ENABLES POLICYMAKERS, PUBLIC HEALTH OFFICIALS, ADVOCATES, AND OTHER STAKEHOLDERS TO ACCESS A WIDE RANGE OF PROGRAMMATIC PEPFAR DATA AND INCLUDES DOWNLOADABLE PDFS, MAPS, DATA VISUALIZATIONS, AND DISTRICT-LEVEL DATA. THE NEW DATABASE COMPLEMENTS AMFARS EXISTING PEPFAR DATABASE (COPSDATA.AMFAR.ORG), WHICH HIGHLIGHTS PLANNED FUNDING BY PROGRAM AREA, COUNTRY AND ORGANIZATION FOR EACH YEAR THAT HAS BEEN PUBLICLY RELEASED. THE DATABASE IS DESIGNED TO HELP PEPFAR IN ITS EFFORTS TO INCREASE DATA TRANSPARENCY AND GENERAL PARTICIPATION IN THE PLANNING PROCESS. IN FEBRUARY 2019, AMFAR, IN CONJUNCTION WITH AVAC, PUBLISHED AN ISSUE BRIEF TITLED NEW HIV TESTING STRATEGIES IN PEPFAR COP19: ROLLOUT AND HUMAN RIGHTS CONCERNS. THE REPORT ANALYZES COUNTRY OPERATIONAL PLAN (COP) GUIDANCE FOR HIV TESTING AND RECOMMENDED POLICIES AIMED AT HELPING TO FIND HIV-POSITIVE PEOPLE WHO HAVE NOT BEEN IDENTIFIED BY OTHER TESTING PROGRAMS AND LINKING THEM TO TREATMENT. IN MAY 2019, AMFAR PUBLISHED A PAIR OF INFOGRAPHICS DEMONSTRATING THE EFFECTIVENESS OF THE GLOBAL FUND TO FIGHT AIDS, TUBERCULOSIS AND MALARIA: A GLOBAL RESPONSE TO HIV REQUIRES THE GLOBAL FUND AND HOW THE GLOBAL FUND IMPROVES PEPFAR INVESTMENTS. THE TWO ORGANIZATIONS ARE THE WORLDS LARGEST AND MOST EFFECTIVE INVESTORS IN HIV TREATMENT AND PREVENTION. IAS 2019 AMFARS PUBLIC POLICY OFFICE PARTICIPATED IN THE 10TH INTERNATIONAL AIDS SOCIETY CONFERENCE ON HIV SCIENCE (IAS 2019) IN MEXICO CITY IN JULY. AMFAR VICE PRESIDENT AND DIRECTOR OF PUBLIC POLICY GREG MILLETT JOINED DR. ANTHONY FAUCI, DIRECTOR OF THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES AT A PRESS CONFERENCE ON "TRANSLATING PROGRESS INTO SUCCESS TO END THE AIDS EPIDEMIC." THE PRESS CONFERENCE COINCIDED WITH THE RELEASE OF A REPORT WITH THE SAME NAME, COAUTHORED BY AMFAR, AVAC, AND FRIENDS OF THE GLOBAL FIGHT AGAINST AIDS, TUBERCULOSIS AND MALARIA. THE REPORT SHOWS PLACES ACROSS THE GLOBAL NORTH AND SOUTH ON TRACK TO END THEIR RESPECTIVE EPIDEMICS AND THE COMMONALITIES BETWEEN THEM. MR. MILLETT ALSO SPOKE AT A JOURNALIST ROUNDTABLE SPONSORED BY AVAC, AND SHARED THE STAGE AT A SEPARATE MEETING WITH WORLD HEALTH ORGANIZATION REPRESENTATIVES AND AMBASSADOR DEBORAH BIRX, U.S. GLOBAL AIDS COORDINATOR, TO DEBATE THE ETHICS OF HIV RECENCY TESTING IN PEPFAR PROGRAMS.
THE GMT INITIATIVE	IMPLEMENTATION SCIENCE AWARDS IN FY2019, AMFARS GRANT MAKING THROUGH THE GMT INITIATIVE CONTINUED TO SUPPORT TWO LARGE IMPLEMENTATION SCIENCE PROJECTS AIMED AT IDENTIFYING BARRIERS TO HIV TESTING, TREATMENT, AND CARE AND STUDYING THE IMPACT OF INNOVATIVE HIV SERVICE DELIVERY MODELS FOR GAY MEN, OTHER MEN WHO HAVE SEX WITH MEN, AND TRANSGENDER INDIVIDUALS (COLLECTIVELY, GMT) IN LOW- AND MIDDLE-INCOME COUNTRIES. AMFAR HAS AWARDED $2.6 MILLION OVER THREE YEARS TO SUPPORT THE STUDIES. DR. CHRIS BEYRER OF JOHNS HOPKINS UNIVERSITY IN BALTIMORE IS LEADING A TEAM OF RESEARCHERS AND COMMUNITY-BASED SERVICES (IN COLLABORATION WITH THE INTERNATIONAL HIV/AIDS ALLIANCE MYANMAR) IN EVALUATING THE EFFECTIVENESS OF PROMISING INTERVENTIONS FOR GMT IN MYANMAR, WHERE INCREASED HIV TESTING AND TREATMENT OPPORTUNITIES ARE BECOMING AVAILABLE. THE RESEARCHERS ARE ASSESSING THE EFFECTIVENESS OF HIV SELF-TESTING DONE IN THE PRIVACY OF ONES HOME, POINT-OF-CARE CD4 TESTING, AND THE USE OF "PEER NAVIGATORS" FAMILIAR WITH THE LOCAL HEALTH SYSTEM TO HELP THOSE NEWLY DIAGNOSED GAIN ACCESS TO HIV TREATMENT AND CARE. IN BANGKOK, DR. NITTAYA PHANUPHAK AND HER TEAM AT THE THAI RED CROSS AIDS RESEARCH CENTRE ARE WORKING TO SHOW HOW INNOVATIVE TECHNOLOGIES SUCH AS GMT-TARGETED WEBSITES USING ONLINE COUNSELING AND SUPPORT CAN BE UTILIZED TO INCREASE RATES OF HIV TESTING AND REFERRALS TO PREVENTION AND TREATMENT PROGRAMS. WORKING IN COLLABORATION WITH ADAMS LOVE, A WEB-BASED HEALTH PLATFORM FOR GMT INDIVIDUALS, AND TWO COMMUNITY-BASED ORGANIZATIONS (SERVICE WORKERS IN GROUP/SWING AND THE RAINBOW SKY ASSOCIATION OF THAILAND), THE TEAM IS COMPARING THE EFFECTIVENESS OF ONLINE SERVICES AND SUPPORT INTERVENTIONS WITH TRADITIONAL CLINIC-BASED HIV SERVICES, AND A HYBRID MODEL THAT COMBINES ELEMENTS OF BOTH STRATEGIES.
POLICIES	FORM 990, PART VI, SECTION B LINE 11 - THE FORM 990 WAS PREPARED BY A NATIONALLY RENOWNED ACCOUNTING FIRM IN CONJUNCTION WITH THE ORGANIZATION'S FINANCIAL DEPARTMENT. A COPY OF THE DRAFT FORM 990 WAS CIRCULATED TO THE FULL BOARD OF TRUSTEES FOR DISCUSSION AND COMMENT. EACH BOARD MEMBER WAS PROVIDED AMPLE OPPORTUNITY TO COMMENT ON THE INFORMATION CONTAINED IN THE 990 PRIOR TO ITS FILING WITH THE INTERNAL REVENUE SERVICE. LINE 12 - EACH OFFICER, DIRECTOR, TRUSTEE AND KEY EMPLOYEE OF AMFAR ("FOUNDATION") IS REQUIRED TO ANNUALLY DISCLOSE ANY CONFLICTS OF INTEREST THAT ARISE BY VIRTUE OF EMPLOYMENT, BOARD SERVICE, OR POSITION WITH THE FOUNDATION. THE FOUNDATION MONITORS COMPLIANCE WITH ITS CONFLICT OF INTEREST POLICY THROUGH AN ANNUAL QUESTIONNAIRE/DISCLOSURE STATEMENT THAT IS DISTRIBUTED TO THESE INDIVIDUALS. POTENTIAL CONFLICTS ARE INVESTIGATED IMMEDIATELY. LINE 15 - AMFAR ("FOUNDATION FOR AIDS RESEARCH") UNDERTAKES A THOROUGH PROCESS TO ENSURE THAT THE COMPENSATION IT PAYS TO ITS TOP MANAGEMENT OFFICIAL AND ALL OF ITS OFFICERS AND KEY EMPLOYEES IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. AN INDEPENDENT CONSULTING FIRM QUALIFIED IN THE AREA OF NONPROFIT COMPENSATION PREPARES AN ANALYSIS OF MARKET COMPENSATION RANGES BY JOB FUNCTION AND PRESENTS IT TO THE COMPENSATION COMMITTEE OF THE BOARD. ON THE BASIS OF THIS INFORMATION, STAFF COMPENSATION IS DETERMINED ACCORDING TO SALARY RANGES APPROVED BY THE COMPENSATION COMMITTEE OF THE BOARD, IN CONSULTATION WITH THE CEO AND CFO. CEO COMPENSATION IS REVIEWED AND DETERMINED BY THE COMPENSATION COMMITTEE OF THE BOARD UTILIZING THE INDEPENDENT CONSULTANT ANALYSIS. AMFAR'S last independent compensation study was conducted in November of 2019 to ensure that the President & CEO's compensation is reasonable given the market in which the Foundation operates.
DISCLOSURE	FORM 990, PART VI, SECTION C LINE 19 - AMFAR MAKES ITS FORM 990 AVAILABLE TO THE PUBLIC BY RETAINING A COPY AT ITS PLACE OF BUSINESS AND ON ITS WEBSITE, WWW.AMFAR.ORG. THE FORM 990 IS LIKEWISE PUBLISHED ON THE INTERNET AT WWW.GUIDESTAR.ORG. THE FOUNDATION'S FINANCIAL STATEMENTS ARE MADE AVAILABLE IN ITS ANNUAL REPORT AND ON ITS WEBSITE. THE FOUNDATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE NOT ORDINARILY MADE AVAILABLE TO THE PUBLIC, BUT, IF REQUESTED, WILL BE PROVIDED AT MANAGEMENT'S DISCRETION.
FUNCTIONAL EXPENSES	PART IX, LINES 1 & 3 THE FOUNDATION FOR AIDS RESEARCH REPORTS ITS GRANTS NET OF GRANT RETURNS OR RECOVERIES. PERIODICALLY, GRANTS REMITTED TO CHARITABLE ORGANIZATIONS ARE RETURNED TO AMFAR FOR A VARIETY OF REASONS. ON SCHEDULES F & I, GRANTS ARE REPORTED IRRESPECTIVE OF WHETHER THEY WERE ULTIMATELY RETURNED TO AMFAR SINCE CATEGORIZING THE "RETURNED" AMOUNTS WOULD BE TIME CONSUMING. THEREFORE, AMOUNTS REPORTED ON PART IX, LINE 1 WILL NOT TIE TO TOTAL GRANTS ON SCHEDULE I; AMOUNTS REPORTED ON PART IX, LINE 3 WILL NOT TIE TO TOTAL GRANTS ON SCHEDULE F.